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ABSTRACT OF THE DISSERTATION
TELOMERASE ACTIVITY IN PROSTATIC FLUID AND
TISSUE AS A MARKER FOR PROSTATE CANCER
by
Zhilian Wang
Doctor of Philosophy, Graduate Program in Biochemistry
Loma Linda University, June, 2000
Dr. Richard E. Beltz, Chairperson
Telomerase is a ribonucleoprotein enzyme that is able to add telomeric repeats to
the ends of eukaryotic DNA to stabilize chromosomes. Telomerase is active in germline
cells, stem cells and tumor cells, but not in most human somatic cells. In this study we
report the extended use of the Telomeric Repeat Amplification Protocol (TRAP) assay for
the detection of telomerase activity in prostate needle biopsy specimens and freshly
collected prostatic fluid. Clinical application of a newly developed PCR-ELISA
telomerase assay method is also evaluated. Multiple sextant needle biopsy specimens
from 56 subjects and prostatic secretion specimens from 72 subjects, with or without
prostate cancer (PCa), were examined. In the needle core group the test results showed
90% sensitivity and 78% specificity for the detection of prostate cancer. In the prostatic
secretion group the sensitivity was 77% and the specificity 84%. Statistical analysis of
both groups revealed that higher positive rates and stronger telomerase activity were
associated with higher Gleason scores and tumor anaplasia. The data from a comparison
of telomerase activity with volume of cancer in the needle cores demonstrated that greater
telomerase activity was always coupled with higher cancer volume. We also

xiv

demonstrated a high correlation between telomerase activity in prostatic secretion
specimens and serum PSA values. In a comparison study, we tested telomerase activity
in 48 prostate needle cores containing or not containing cancer cells, and in 18 prostatic
fluid specimens from patients with or without PCa by both the PCR-ELIS A method and
the TRAP assay. The assay results showed high correlation between two methods.
In conclusion, telomerase activity was reliably detected by each method in
specimens of both types. It may be clinically meaningful to apply this new assay system
for determining telomerase activity because by its sensitivity it provides valuable
information for early diagnosis, and beyond that for therapeutic evaluation of prostate
cancer patients.
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I. INTRODUCTION

A.

TELOMERES
1.

Sequence Organization

Telomeres are the specialized protein-DNA structures at the ends of eukaryotic
chromosomes (Muller, 1938; McClintock, 1941; Blackburn, 1994). The nucleotide
sequence organization is quite conserved in all eukaryotes. These telomeric DNA
sequences can be double-stranded telomeric repeats and/or single-stranded tails at the
very ends of the chromosomal DNA.
The double-stranded telomeric repeats consist of short (6-8 bp), tandemly
repeated DNA sequences (Blackburn, 1991). For example, the first telomeric repeat
sequence identified, the one for Tetrahymena, is CCCCAA/TTGGGG (Blackburn and
Gall, 1978), while the repeat for humans and other vertebrates is CCCTAA/TTAGGG
(Moyzis et ah, 1988; Meyne et ah, 1989). The number of repeats per telomere apparently
varies among different chromosomes of the same cell, among the same chromosome in
different cells, or among organisms (de Lange et ah, 1990; Mumane et ah, 1994;
Klobutcher et ah, 1981; Kipling and Cooke, 1990; Starling et ah, 1990). This is
concluded from a Southern analysis for measuring the average size of the chromosome
terminal restriction fragments (TRFs). In humans, telomeres are composed of 500 to
more than 2,000 repeats, thus containing 3 to approximately 12 kb of telomeric repeat
sequences. The actual lengths of the telomeric repeats are the result of the mechanisms of
telomere dynamics (Zakian, 1995; Slijepcevic, 1998; Pardue and DeBaryshe, 1999). One
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of the important features of these repeat sequences is their polar arrangement. Because of
the particular base composition of the repeats, one of the strands rich in clusters of G
residues is termed the G strand. It is always oriented to form the extreme 3'-end of the
chromosome and its complement is the C strand. The G strand of human telomeres may
be reiterated in tandem for up to 15 kb (Moyzis et ah, 1988; Morin, 1989). The very ends
of the chromosomal DNA are single-strand tails. These 3' terminal G-strand overhangs
usually consist of 12-20 bases (Henderson and Blackburn, 1989).
Some experiments reveal that the linear G-rich sequences are able to form a large
and polymorphic class of higher-order structures, such as G-G base pairs and fourstranded structures called G-quadruplexes, G-quartets or G4-DNA, by interacting with
some specific monovalent and divalent cations, e.g. potassium, sodium, etc. (Henderson
et al., 1987; Williamson et al., 1989; Williamson, 1994; Wellinger and Sen, 1997). These
alternatively folded structures of telomeric DNA have a high thermodynamic stability and
extraordinarily slow kinetics of formation and unraveling. The possible biological roles
for G-quadruplexes are associated in vivo with meiotic or mitotic pairing (Sen and
Gilbert, 1988), cell-cycle controls (Wellinger et al., 1993), DNA recombination (Venczel
and Sen, 1996), control of telomere replication, and inhibition of telomerase (Zahler et
al., 1991).
2.

Telomere-Binding Proteins

These binding proteins can be divided into two classes: double-stranded DNAbinding proteins, e.g. Raplp and Tazlp in yeast (Shore and Nasmyth, 1987; Cooper et al.,
1997), TRF1 and TRF2 in humans (Chong et al., 1995; van Steensel and de Lange, 1997,
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Broccoli et al., 1997), and single-stranded DNA end-binding proteins, e.g. the a/p
heterodimer protein in Oxytricha (Fang and Cech, 1993), cdc 13p in yeast (Nugent et al.,
1996), TEP in Tetrahymena (Sheng et ah, 1995), and telomerase (Greider, 1996).
The possible biological roles for some of these proteins have been identified.
Examples are TRF1 and TRF2 from humans. Both proteins have helix-tum-helix motifs
similar to the Myb DNA-binding fold. This motif has been called the telobox because of
its tendency to be present in telomere-binding protein (Bilaud et al., 1997; Bianchi et al.,
1997). Both TRF1 and TRF2 appear to be present throughout the cell cycle on most
human telomeres. TRET is considered to be a negative regulator of telomere length
maintenance (van Steensel and de Lange, 1997), while TRF2 plays a role in the
protection of chromosome ends from end-to-end fusion by maintaining chromatin
structure (van Steensel et al., 1998).
3.

Telomere Structures

Classically, eukaryotic telomeres are considered to be made up by linear doubleor single-stranded telomere repeats plus many proteins bound to them (Figure 1.1 A).
Recently, the research on telomeres has demonstrated that high percentages of
mammalian molecules have loop structures in vitro or in vivo in which the free 3' G
strand overhangs are tucked back inside the double-stranded DNA several kilobases away
from the terminus, forming the big t loops, and the single-strand tails invade the doublestranded regions to be base paired with the internal complementary tracts, forming the
relatively small D loops. Double-stranded DNA-binding proteins bind along the length
of the telomere repeats, including TRF1 and TRF2 in humans. TRF2 is specifically
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bound at the bases of the loop junction, suggesting that TRF2 mediates the formation or
stabilization of t loops (Figure 1.1B). The size of the t loop is determined by the length
of the telomere, indicating that chromosomes containing long telomeres form longer
loops than those having short telomeres. Again, the t loop structure is dynamic and
reforms after each round of DNA synthesis (Griffith et ah, 1999). Compared with the
classical model, the discovery of “D-loop-t-loop” structure in mammalian telomeres
provides a new explanation for the mechanisms that mediate telomere function.
4.

Telomere functions

The primary function of telomeres is to protect chromosome ends from end-to-end
fusion, recombination, and degradation. The molecular mechanism of this telomere
function has been proposed to depend on both a specific DNA sequence (Williamson et
ah, 1989; van Steensel et ah, 1998) and telomere binding proteins (Griffith et al., 1999).
It has been demonstrated that inhibition of TRF2 results in immediate activation of the
ATM/p53-dependent DNA damage checkpoint pathway, leading to cell cycle arrest and
apoptosis (Karlseder et al., 1999). Discovery of the “D-loop-t-loop” structure further
confirms that both telomere sequence and binding proteins work together to sequester
natural chromosome ends, acting to avoid an inappropriate DNA damage response. This
t loop model not only explains how cells can distinguish randomly broken DNA from
natural chromosome ends, but also infers that t loops may fail to form in cells with very
short telomeres, causing genome instability as well as the cellular phenotypes (senescence
and crisis) associated with telomere shortening.
The second essential function of telomeres is to allow access to telomerase and to
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maintain telomere length. Third, telomeres are also involved in the replication of
chromosome ends.
5.

Telomere Dynamics

Besides the roles mentioned above, the telomere has one special feature that
distinguishes it from the rest of the chromosome. This feature is the constant loss and
replenishment of telomeric DNA sequence in a cell cycle-dependent manner, which is
called “telomere dynamics”.
One of the molecular mechanisms for telomere shortening is related to the DNA
“end replication problem”. According to our understanding of DNA replication, the
leading strand of the replication fork proceeds continuously to replicate one strand of
original DNA for each cell division, while lagging strand synthesis is discontinuous,
consisting of Okazaki fragments which initiate with labile RNA primers. After RNA
primer removal and Okazaki fragment extension and ligation, the most 5' Okazaki
fragment remains incomplete since the RNA primer cannot be replaced. If the S'-terminal
Okazaki fragment does not initiate directly opposite the 3' end of the template DNA, there
will be additional bases incompletely replicated. This replication mechanism predicts the
progressive shortening of chromosomal DNA at the 3' ends over multiple cycles of
replication in normal somatic cells (Olovnikov, 1973; Watson, 1972; Levy et al., 1992).
The conventional model of telomere shortening, based on the end replication problem,
predicts that at the end of S-phase, half of the chromosome ends will have blunt DNA
ends and the other half short 3' tails (Lingner et al., 1995) (Figure 1.2A). However, the
conventional model alone can’t account for the actual loss of telomeric DNA for two

7

Figure 1.2. The DNA “end replication problem” (vertebrate DNA sequence shown).
A. Conventional model. B. Modified model. Lagging strand synthesis produces series
of Okazaki fragments attaching to short RNA primers (boxes) in both models. According
to the conventional model, degradation of the primers, gap repair, and ligation replace all
but the last primer resulting in a gap in half of the 5' termini. According to the modified
model, DNA is lost from both ends of the chromosomes, owing to degradation of the 5'
strand by an S-phase-specific exonuclease activity resulting in long 3' overhangs at both
ends. (Adapted from Slijepcevic 1998.)
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reasons: 1) in yeast and human cells 100% and 80-100% of chromosome ends,
respectively, have long 3' tails at the end of the S-phase (Wellinger et ah, 1996; Makarov
et ah, 1997); 2) the conventional model predicts that the average number of lost base
pairs per telomere per cell cycle should be 0.25 times the length of the RNA primer,
estimated to be 8-12 bp in length, whereas the actual loss of telomeric DNA sequences in
human fibroblasts is 77 bp per telomere per cell cycle (Makarov et ah, 1997). To explain
the difference between the rates of expected and observed loss of telomeric DNA, a
modified model has been proposed (Wellinger et al., 1996; Makarov et ah, 1997) (Figure
1.2B). This model predicts that S-phase-specific exonuclease activity converts blunt
DNA ends into ends with long 3' tails in a cell cycle-dependent manner. Therefore,
telomeric DNA is lost as a result of two mechanisms, the end-replication problem and Sphase-specific exonuclease activity.
The telomere hypothesis of cell aging and immortalization (TFICI) suggests that
telomere shortening in the absence of telomerase is the mitotic clock for replicative
senescence in normal somatic cells (Harley, 1991; Harley et al., 1992; Holt et al., 1996)
(Figure 1.3). The number of cell divisions is registered by the gradual loss of telomeric
nucleotide sequences. As the telomeres become shortened to a critical length where they
no longer protect the chromosome ends from recombination or degradation, signals are
sent to the cell to exit from the cell cycle (Ml). Replicative senescence is thus
established. Normal human somatic cells in culture undergo replicative senescence
normally after 40-70 population doublings (PDs). The hypothesis for the induction of
Ml postulates that a shortened chromosome denuded of telomeric repeats produces a
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DNA-damage signal, which activates ATM gene expression and induces p53 and p21.
Then p21 inhibits the cyclin-dependent kinases, which are consequently prevented from
phosphorylating pRb. On the other hand, the pl6 gene, CDKN2A, is activated. Protein
pl6 inhibits a holoenzyme complex containing a cyclin D and a cyclin-dependent kinase
(cdk4 or cdk6), and thereby inhibits phosphorylation of pRb. The presence of
unphosphorylated pRb coupled with other actions of p53, p21, and pi6 results in Ml
arrest (Parkinson et al., 1997; Huschtscha and Reddel, 1999). If the Ml cell cycle
checkpoint or the Hayflick limit can be bypassed by mutating the tumor suppressor
genes, e.g. P53 and Rb genes, only 1 x 10'7 cells can escape senescence and continue to
divide with further telomere loss and chromosome instability. At crisis (M2), most cells
die. However, some cells can further escape from this “crisis” phase by activating
telomerase or by other mechanisms to stabilize their short chromosome ends. These
“immortal” cells could maintain relatively long telomeres and possess unlimited
proliferative potential, which is one of the characteristics of malignant tumor cells.
The telomeric DNA loss is replenished by two mechanisms: 1) active telomerase,
a reverse transcriptase that synthesizes telomeric sequences using its own RNA
component as a template (Greider and Blackburn, 1989; Shippen-Lentz and Blackburn,
1990); 2) telomerase-independent mechanisms, including the ALT (alternative
lengthening of telomeres) pathway (Bryan et al., 1995 & 1997). It might be possible that
ALT is caused by non-reciprocal recombination between telomere repeats, resulting in a
gain of repeats by short telomeres. However, the exact mechanism of ALT is still unclear
(Bryan et al., 1995 & 1997).
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In single-cell organisms, human germ-line cells, and a high percentage of
malignant tumor cells, telomere shortening and elongation mechanisms are well balanced
so that there is no loss of telomeric DNA. However, the telomere shortening mechanism
dominates because of a lack of telomerase activity in human normal somatic cells
(Counter et ah, 1992; Kim et ah, 1994).
Mechanisms for telomere dynamics are well controlled at many levels. First,
there are cells dependent upon telomere-binding proteins to determine optimal telomere
length. For example, Rap Ip in S. cerevisiae, Tazlp in £. pombe, and TRF1 in humans,
the double-stranded DNA-binding proteins, act to regulate telomere dynamics negatively
(Shore, 1997). Thus, when the number of protein binding sites is decreased, telomerase is
activated to elongate the telomere sequence. On the contrary, the presence of a sufficient
number of protein molecules on telomeres suppresses telomerase activity. Mutation of
the Tazl gene causes massive elongation of telomeres (Cooper et al., 1997), and a long
term overexpression of TRF1 in a telomerase-positive human tumor cell line leads to a
gradual and progressive telomere shortening (van Steensel and de Lange, 1997). Second,
the binding proteins, which do not bind to a polydeoxynucleotide sequence directly but
can bind to telomere-binding proteins, affect telomere accessibility to regulate sequence
length. For example, tankyrase, which can bind to TRF1 but not to any telomere, is
involved in this process. The active center of the enzyme, PARP [poly(adenosine
diphosphate-ribose) polymerase], can catalyze a reaction in which ADP-ribose is
transferred from NAD+ to TRF1. This results in the dissociation of TRF1 from the
telomere sequence, enabling telomerase to replace DNA lost during replication (Smith et
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al., 1998). Third, the possible G-G base pairs, G-quadruplexes, and G-quartets at the
chromosome ends act as negative regulators by blocking telomerase access to telomeric
DNA (Zahler et ah, 1991). Fourth, telomerase itself could be induced to have an activity
change which is discussed below. Finally, telomere length in individual chromosomes is
specifically regulated by a centromere position effect (CPE) and repetitive subtelomeric
DNA sequences (Slijepcevic, 1998).

B.

TELOMERASE
Telomerase activity was first identified in Tetrahymena (Greider and Blackburn,

1985) and later in several other eukaryotes including Oxytricha, Euplotes, yeast, mice,
and humans, etc. (Greider, 1996; Morin, 1989; Cohn and Blackburn, 1995). Telomerase
is a ribonucleoprotein (RNP) enzyme whose activity depends on both its RNA and
protein components, which was confirmed by loss of activity after pre-treatment with
either RNase or heat (Greider and Blackburn, 1987; Morin, 1989).
1.

Telomerase RNA Subunit

The telomerase RNA (TR) of the ciliated protozoan Tetrahymena was the first
telomerase subunit to be identified (Greider and Blackburn, 1987). The observation that
it contained a region with a sequence complementary to the Tetrahymena telomeric repeat
suggested that the RNA might serve as a template for telomeric DNA replication (Greider
and Blackburn, 1989). RNA mutagenesis studies further confirmed that changes in the
RNA template resulted in the synthesis of the corresponding mutant DNA sequence
(Feng et ah, 1995; Singer and Gottschling, 1994). With information about TR subunits
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isolated from a variety of species (Greider, 1996), it could be concluded that these TR
subunits exhibit considerable divergence in terms of both their nucleotide sequence and
their size, even though they share an essential and conserved function (Table 1.1). TRs
range in size from about 160-190 nucleotides in the ciliates to approximately 1300
nucleotides in the yeasts. Each of the TRs contains the appropriate template sequence to
synthesize telomeric repeats. For example, the TR length in humans is about 450 bases,
and its template sequence is ‘CUAACCCUAAC’ (Feng et ah, 1995). The TR template
region can be divided into two domains, a templating domain and a binding domain. The
binding domain, five bases in length in humans, is located at the 3' end of the template
region and binds the 3' terminus of the DNA primer or telomeric sequence. The
templating domain, six bases in length in humans, is at the 5' end of the template region
and specifies the addition of the complementary deoxynucleotides. Some experiments
have shown that bases at the 3' end of the binding domain are used for binding the 3'
terminus only, while bases at the 5' end of the binding domain can be used both to pair
with the terminus and to act as a template for nucleotide addition (Autexier and Greider,
1994 & 1995; Gilley et ah, 1995; Gilley and Blackburn, 1996). This means that the 3'
terminus of the DNA primer or telomeric sequence should anneal with at least the entire
binding domain for successful binding and further DNA elongation.
In contrast with low conservation in their primary sequences, it has been predicted
that TR subunits have a highly conserved secondary structure (Romero and Blackburn,
1991; Nugent and Lundblad, 1998). The TR secondary structure is predicted to consist of
a series of stem, stem-loop, and pseudoknot elements (Lingner et ah, 1994; Nugent and

16

Table 1.1. Telomerase RNA subunits
Organism

Telomere sequence

RNA template sequence

Tetrahymena
Euplotes
Oxytricha
Human
Mouse
S. cerevisiae
K. lactis

TTGGGG

CAACCCCAA
CAAAACCCCAAAACC
CAAAACCCCAAAACC
CUAACCCUAAC
CCUAACCCU

TTTTGGGG

TTTTGGGG
TTAGGG
TTAGGG
TG(l-3)
TXT GATTAGGT AT GT-

CACCACACCCACACAC
UCAAAUCCGUACACC-

AAUACCUAAUCAAA

GGTGTACGGA
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RNA length
160
190
190
450
450
1300
1300

Lundblad, 1998), which suggests the existence of a conserved three-dimensional fold.
Structural observations and measurements will be required to confirm the predicted
folding. The role of the secondary and tertiary structural elements in TR subunits may be
not only to carry the template, but also to serve as a scaffold for the recruitment of
specific accessory protein components of the telomerase. Fractionation of telomerase
activity has confirmed that the RNA subunit is bound with multiple protein components,
especially the telomerase catalytic subunit (Collins and Gandhi, 1998; Lingner and Cech,
1996).
2.

Telomerase Protein Components

Compared to the identification of TR subunits, telomerase protein components
have proven to be more elusive, being first purified from Tetrahymena in 1995. Two
protein components, p80 and p95, were found to be specifically associated with the RNA
subunit. However, their specific functions were unclear, even though evolutionary
conservation suggested that both proteins might have important roles in telomere
replication (Collins et al., 1995).
At least two protein components, the catalytic subunit and telomerase-associated
protein 1, have been determined to be part of telomerase. The catalytic subunit of
telomerase protein components was unambiguously identified and cloned in 1997
(Lingner et al., 1997). The catalytic subunits from other species, including humans, were
subsequently identified and cloned (Harrington et al., 1997b; Killian et al., 1997;
Meyerson et al., 1997; Nakamura et al., 1997; Nakayama et al., 1998). Data accumulated
for telomerase catalytic subunits from evolutionarily diverse organisms suggest that this
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protein subunit is quite conserved among eukaryotes, and the protein sequences and
functions are similar to previously known reverse transcriptases (RTs) in their active site
region. That these catalytic subunits contain the polymerization activity of telomerase
was also confirmed by site-directed mutagenesis of aspartate amino acid residues that are
highly conserved across the catalytic subunit and RT families, and by the reconstitution
of telomerase activity from the in vitro transcribed and translated human telomerase
catalytic subunit and TR subunits (Lingner et ah, 1997; Harrington et ah, 1997b; Counter
et ah, 1997; Weinrich et ah, 1997). Therefore, telomerase catalytic subunits are termed
Telomerase Reverse Transcriptases (TERTs). The Genome Database Organization
(GDO) has approved the name hTERT for the human gene, which was formerly called
hTRT (Nakamura et ah, 1997), hEST2 (Meyerson et ah, 1997), TCS1 (Killian et al.,
1997), or TP2 (Harrington et al., 1997b).
The primary protein sequences of the RT motifs in the TERTs from several
species, including humans, contain at least eight characteristic motifs, among which
seven of them (1, 2, A, B’, C, D, and E) are shared with RTs, while one of them (T) is
unique (Lingner et al., 1997; Nakamura et al., 1997) (Figure 1.4A). Pairwise
comparisons of these sequences show a high similarity among the RT motifs of different
TERTs, and a higher similarity among more evolutionarily related organisms such as
mice and humans or within the family of ciliate proteins (Bryan et al., 1998). There is
little similarity between the RT motif regions of conventional RTs and those of TERTs,
but they share a set of conserved and/or semiconserved amino acid residues (JacoboMolina et al., 1993), which might play important functional and architectural roles
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consistent with the mechanistic differences between telomerases and RTs. However,
TERTs are structurally and phylogenetically related to RTs (Nakamura and Cech, 1998).
The unique T motif of TERTs is functionally required for telomerase activity (Weinrich
et ah, 1997). In addition, the TERTs from the ciliate family have a region of homology
(the CP motif) with unknown function located N-terminal to the T motif. The relatively
big space between the RT motifs in the TERTs is different from that in known RTs,
indicating a structural insertion (Figure 1.4B).
The crystal structures of TERTs have not been determined yet. However, their
structures, especially the RT motif regions, might be predicted based on the threedimensional structures of conventional RTs that are known, such as HIV RT. Generally,
the TERTs are reminiscent of the shape of a right hand, containing the fingers, palm and
thumb domains, while the (3af3-pa(3 secondary structural motifs form these domains
(Figure 1.4B). The active site, defined by a triad of aspartate residues (Lingner et ah,
1997; Harrington et ah, 1997b; Counter et ah, 1997; Weinrich et ah, 1997), is located in
the palm domain. This triad of aspartate residues serves to coordinate the divalent cations
(Mg2+) that are required for catalysis. The 3' hydroxyl of the DNA primer and the dNTP
positioned for addition to the primer strand are also positioned close to this catalytic triad.
Motif E (called the primer grip) in TERTs has sequence features that are different from
the motif in RTs, reflecting the differing primer specificities of these two enzyme
families. Motif T in TERTs might reflect the requirement that telomerase must carry its
own RNA template (O’Reilly et ah, 1999). In detail, the dominant aromatic residues in
the T motif might serve to stabilize and orient the single-stranded template region.
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Nonspecific van der Waals’ interactions between bases and aromatic residues could also
favor movement of the template, which is necessary during DNA synthesis.
Another protein component of mammalian telomerase is telomerase-associated
protein 1 (TP1), which was identified and cloned in 1997 (Harrington et al., 1997). The
primary protein sequence of 2,627 amino acid residues contains some characteristic motif
regions. These motif regions include a 30-amino acid sequence repeated at the NH2terminus, three regions in the NH2-terminal one-third of TP1 having a high sequence
similarity to Tetrahymena p80, an adenosine triphosphate/guanosine triphosphate
(ATP/GTP) binding motif starting at amino acid 1179 of the mouse sequence, and 16
putative WD40 repeats at the COOH-terminus (Figure 1.5). The NH2-terminus of TP1,
which shows a high homology to Tetrahymena p80, specifically interacts with telomerase
RNA (TR), and TP1 is associated with telomerase activity in vivo. These results suggest
that the TRs may share sufficient secondary structure to be recognized by a conserved
RNA-binding motif, although there is a significant difference in sequence between the
TRs of ciliates and mammals (Greider, 1996; Romero and Blackburn, 1991; Nugent and
Lundblad, 1998). TP1 may form one or more propeller structures, which are originated
from those WD40 repeats, to mediate interactions with other telomerase or telomere
binding proteins. Other data suggest that TP1, which is quite conserved from ciliates to
humans, may not be a rate-limiting or essential subunit of telomerase.
3.

Telomerase Functions

Structurally and functionally, telomerase can be considered an RNA dependent
DNA polymerase, or reverse transcriptase, that uses its own RNA template. Its basic
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function is to extend the 3' end of telomeres by de novo synthesis of the G-rich telomeric
repeat DNA (Greider and Blackburn, 1989; Shippen-Lentz and Blackburn, 1990). There
are several models to explain the mechanism of the telomerase reaction. A simplified
model of it, or the general telomerase reaction mechanism (Figure 1.6), is a reiterative
copying of the templating domain. The process involves annealing of the 3' end of the
telomeric sequence or of the primer to the binding domain of the RNA template, resulting
in an elongation phase where deoxyribonucleotides are sequentially added to the 3' end of
the telomeric sequence or of the primer, followed by a slower translocation phase in
which the relative position of telomerase and the telomere or the primer advance one
repeat, thus positioning the enzyme for another elongation phase. In the annealing phase,
the 3' end of the telomeric sequence or DNA primer aligns by base pairing with the
binding domain of the TR template region, which has been determined by mutagenesis
experiments not only to provide the templating function, but also somehow to participate
in the catalytic activity of the enzyme (Prescott and Blackburn, 1997). The TERT of
telomerase also participates in this step by the recognition of the template 3' hydroxyl.
Since the TR subunit carrying the template is anchored directly or indirectly to the TERT
that constrains the relative movement in the following elongation and translocation
phases, the RNA template must move regionally in the direction of the primer strand and
‘reprime’ at its original starting position. Fortunately, the TERT is structurally flexible
and favors this movement, inferring that telomerases are conformationally dynamic
enzymes during telomere replication. The TERT plays a key role in catalyzing these
processes.
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Figure 1.6. The general telomerase reaction mechanism. In the annealing phase, the
3' end of the telomeric sequence or DNA primer aligns via base pairing with the binding
domain of the TR template region, followed by extension of the telomere repeat
(lowercase letters) in the elongation phase until the extended product reaches the 5' end of
the template domain. Translocation then moves the extended DNA back one repeat
relative to the template domain, either repositioning it for an another round of elongation
or releasing it from the TR subunit. (Adapted from Morin 1997.)
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Based on the model above, rebinding the released DNA is usually necessary after
a translocation phase, since telomerase catalyzes a processive reaction. Recognition and
alignment of the 3' end of the telomeric sequence or DNA primers by telomerase is
mediated by base-pairing with the RNA template. However, some experiments in vitro
show that telomerase better utilizes long primers (10-12 nucleotides) than shorter ones (46 nucleotides) with identical 3' termini, and primers with a G-poor region upstream are
less processive than those with a G-rich region upstream, even though they have identical
lengths and 3' termini (Morin, 1991; Lee and Blackburn, 1993). This indicates that
contacts other than the primer/template pairing exist and suggests that the telomerase has
two distinct sites of primer interaction. The second model, termed the two-site model
(Chamberlain, 1992; Morin, 1997) (Figure 1.7), has provided a new explanation for the
processivity of telomerase and its reaction. Compared to the old model, a second site,
termed the upstream site, or the anchor or lagging site (Gilley and Blackburn, 1996;
Collins and Greider, 1993), binds the primer about 8-15 nucleotides upstream of the 3'
end and may provide a significant fraction of the overall binding energy. In the two-site
model, the first several steps are similar to those in the old model, but after an elongation
phase, DNA products can be either released from the telomerase or kept as a
DNA/telomerase interaction at the upstream site, which increases the probability of
rebinding the 3' terminus in the binding region of the template and achieves a processive
reaction. The ratio of DNA release at the upstream site to DNA reannealing at the
template site determines the processivity of the reaction. If DNA products choose to
maintain an interaction with the telomerase at the upstream site after the 3' end is released
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Figure 1.7. The two-site model for the telomerase reaction mechanism. Step 1:
binding or annealing of the DNA primer to the two sites on the telomerase, note that this
primer has a G-rich upstream region. Step 2: addition of nucleotides to the 3' end of the
primer. Step 3: melting of the DNA/template duplex, note there is no dissociation at the
upstream site. Step 4: decision between product release or translocation. Product is
released (step 4A) when dissociation occurs at the upstream site before the 3' end of the
DNA re-anneals to the binding domain of the RNA template. Translocation occurs (step
4B) when the DNA re-anneals before dissociation at the upstream site. Step 5: two
possible paths for continuation of the reaction. Step 5A: the sliding model. The upstream
site can rebind the DNA six nucleotides further downstream, followed by another round
of nucleotide addition or elongation (step 6). Step 5B: the loop-out model. The DNA
occupying the upstream site is not released, the new DNA remains looped out between
the upstream and template sites, and nucleotide addition occurs at the 3' end. Note that in
the sliding model the G-rich region of the primer is removed from the upstream site,
while in the loop-out model the G-rich region remains bound to the upstream site. The
two models differ in what DNA occupies the upstream site, this could affect the
processivity of the telomerase reaction. Step 7: return to step 2 for continuation of the
previous steps. (Adapted from Morin 1997.)
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from the template, there are two possible paths or sub-models for continuation of the
reaction. In the sliding model for further reactions, a two-site translocation occurs,
followed by another round of nucleotide addition, while in the loop-out model the DNA
sequence occupying the upstream site is not released, the new DNA remains looped out
between the upstream and template sites, and nucleotide addition occurs at the 3' end.
Thus, translocation occurs only in one of two binding sites, or in the template site. These
two sub-models differ with respect to which DNA occupies the upstream site. This could
affect the processivity of the telomerase reaction.
In addition to a reverse transcriptase activity, telomerase also exhibits a
nucleolytic cleavage activity that removes nucleotides from the 3' terminus of the
chromosomal strand prior to telomere synthesis (Collins and Greider, 1993; Greene et al.,
1998). This may provide a proof-reading function or play a role in enzyme processivity.
3.

Telomerase Regulation

Telomerase activity could be regulated at many levels. First of all, the expression
of an essential telomerase subunit can be regulated at the transcriptional and translational
level. Recent data show that hTR and hTERT are sufficient to reconstitute telomerase
activity in vitro (Weinrich et ah, 1997; Beattie et al., 1998), whereas hTR is detected in
most human somatic cells that lack detectable telomerase activity (Feng, 1995, Bodnar,
1998). Expression of hTERT seems to be highly regulated and is associated with
telomerase activity (Killian et al., 1997; Meyerson et al., 1997; Nakamura et al., 1997),
suggesting that hTERT is a rate-limiting determinant of telomerase activity and that the
control of hTERT synthesis might be an important mechanism for modulating telomerase
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activity. The hTERT gene, which is located on human chromosome 5p (Meyerson et ah,
1997), has been found to encompass more than 37 kb and to consist of 16 exons. The
usage of alternative splice consensus sequences in intron or exon regions results in the
hTERT insertion and deletion variants (Wick et ah, 1999; Ulaner et ah, 1998), which
causes a complex pattern of protein expression. This conclusion is consistent with the
data from another group showing that the TERT gene encodes different large proteins
with molecular weights between 130 and 180 kDa (Harrington et ah, 1997b). Gel shift
analysis reveals several consensus binding sites for the oncoprotein c-Myc and the
transcription factor Spl in the promoter region of the TERT gene (Wick et ah, 1999;
Takakura et ah, 1998; Horikawa et ah, 1999), suggesting that the Myc protein plays a role
in telomerase activation. Further experiments show that overexpression of c-Myc
significantly increases transcription activity of the promoter of the TERT gene, induces
TERT gene expression and leads to increased activity of telomerase (Wang et ah, 1998;
Wu et ah, 1999; Greenberg et ah, 1999).
Second, telomerase activity can be regulated at the enzymatic level. The data
from a few research groups suggest that both protein kinase Ca (PKCa) and Akt protein
kinase (a serine/threonine kinase) can activate telomerase by phosphorylation of hTERT,
whereas protein phosphatase 2A (PP2A) reversibly inhibits telomerase activity by protein
dephosphorylation in vivo and/or in vitro (Li et ah, 1998; Kang et ah, 1999). The data
from other groups show that telomerase action in vitro is much more processive with
enzyme derived from Tetrahymena or humans than that from mice (Prowse et ah, 1993).
Because mouse telomeres are exceptionally long (Kipling and Cooke, 1990), there may
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be accessory factors in vivo that increase the processivity of mouse telomerase.
Furthermore, the reaction conditions in vitro affect the catalytic activity and processivity
of telomerase. The catalytic activity of human telomerase increases as temperature (up to
37 °C), concentrations of dGTP, primer, and K+ are increased, while the processivity
decreases as temperature and concentrations of primer and K+ are increased (Sun et al.,
1999).
Third, introduction of wild-type chromosome 3 into cancer cells results in a great
decrease in telomerase activity, accompanied by a reduction of hTERT mRNA expression
and permanent growth arrest (Mehle et al., 1998; Tanaka et al., 1998; Vieten et al., 1998;
Cuthbert et al., 1999). These data suggest that wild-type telomerase repressor genes on
the short arm of chromosome 3 could inhibit telomerase activity in tumor-derived cell
lines, resulting in progressive telomere shortening and reprogramming of cellular
senescence. The telomerase repressor region on chromosome 3p has been narrowed to
3p21.3-p22 and 3p 12-21.1 (Cuthbert et al., 1999), 3pl3-pl4.2 (Vieten et al., 1998),
3pl4.2-p21.1 (Tanaka et al., 1998), and 3pl4.2-p21.2 and 3p24.1-p24.3 (Mehle et al.,
1998). More precise mapping of the 3p region and the detailed biochemical mechanism
are still unclear.
Finally, telomerase could be regulated by telomere accessibility. As discussed
above, the yeast Raplp, Tazlp, and human TRF1 proteins, as negative regulators, bind to
telomeres tightly, preventing telomerase access to telomere-repeat tracts and DNA
sequence elongation (Shore, 1997; van Steensel and de Lange, 1997). DNA structure
could also affect telomere replication. For example, the G-quartets in the G strands may

34

inhibit the ability of the latter to serve as primers for telomerase as well as acting to
reduce the extent of telomerase elongation (Zahler, 1991). Therefore, the formation of Gquartets might affect both telomere accessibility to telomerase and telomerase
processivity.

C.

TELOMERASE AND HUMAN CANCERS
1.

Telomerase in Malignancy

Based on current knowledge in cancer biology, progression to a cancerous state in
a cell requires the accumulation of a series of genetic alterations or mutations. For
instance, alternative gene mutations induce a clone of normal somatic cells to lose the
ability to respond to growth inhibitory signals, allowing cell division without the specific
growth stimulatory signals. Hyperproliferation can speed up telomere shortening in the
cells. Telomerase could be therefore activated in a clone of the cells to elongate the
shortened telomeric sequences and to stabilize chromosome ends if additional mutations
occur, according to the THCI. The cell-containing telomerase activity indicates that it is
potentially immortal, but not necessarily malignant. The attainment of cell immortality
does not necessarily induce unregulated rates of cell proliferation or metastasis, but only
gives the cells the proliferative capacity to accumulate the necessary mutations to become
malignant (Holt et al., 1996). Therefore, more mutations must be required for those
immortal cells to progress to invasive and then metastatic states. Because cancer is
diverse, some tumors may need only a few mutations in order to become malignant and
may not exhaust the normal limits of proliferation number before they cause disease.
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These types of cancer would be expected to be both mortal and negative for telomerase
activity. Because particular types of tumors follow the same pathway of events,
telomerase activity could serve to stage a particular tumor type.
2.

Telomerase as a Diagnostic Marker of Malignancy

Since telomerase activity was first identified in Tetrahymena in 1985, attempts to
detect telomerase activity in human cells were not very successful until studies were done
with cultured HeLa cells, a human cancer cell line (Morin, 1989), and subsequently with
tumor tissue samples from human ovarian and the B-cell cancers, using a primer
extension method (Counter et ah, 1994; Nilsson et ah, 1994). However, technical defects,
e.g. low sensitivity, limited further research until a highly sensitive PCR-based
telomerase assay, the Telomeric Repeat Amplification Protocol (TRAP), was introduced
(Kim et ah, 1994). At present, exponentially accumulating data show that telomerase
activity is detectable in about 85% of human cancers and in 14% of benign or
premalignant neoplasms, but not in most normal human somatic cells and tissues (Kim et
ah, 1994; Shay and Wright, 1996; Shay and Bacchetti, 1997). A weak telomerase activity
in benign neoplasms may indicate the presence of a small subset of malignant cells mixed
with benign cells, perhaps signifying disease progression, and seems to correlate with
clinical outcome in a number of cancer types (Schwartz et ah, 1995; Sommerfeld et ah,
1996; Zhang et ah, 1998). These results suggest that telomerase activity may be a
promising molecular marker for the diagnosis of human cancer and may play a useful role
in early cancer diagnosis and prognosis. However, there remain some problems with
regard to the specificity of telomerase as a cancer marker.
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The enzyme is active in some non-neoplastic populations of cells. A low level of
telomerase activity is detected in certain germ line cells and during early human
embryogenesis, even though it is repressed upon tissue differentiation during
development (Wright et ah, 1996). This repression generally correlates with the time of
tissue differentiation. Telomerase is also active in the proliferative cells of renewal
tissues, including activated lymphocytes (Hiyama et ah, 1995; Broccoli et ah, 1995; Chiu
et ah, 1996), specific proliferating epithelial cells in the breast (Tsao et ah, 1997),
endometrial tissues (Kyo et ah, 1997), the basal layer of normal skin (Harle-Bachor and
Boukamp, 1996; Taylor et ah, 1996), and the crypts of the intestine (Hiyama et ah, 1996).
Finally, telomerase activity has been shown to be present at low levels in populations of
haematopoietic stem cells in human bone marrow (Chiu et ah, 1996; Engelhardt et ah,
1997; Yui et ah, 1998). The presence of telomerase activity from the cells above in
tumor specimens might hamper the clinical application of telomerase assays, especially in
specimens from tissues having active enzyme present, e.g. leukemias and uterine
endometrium (Broccoli et ah, 1995; Kyo et ah, 1997).
Theoretically, the diagnosis of cancer is more appropriately achieved in
specimens obtained by mini- or non-invasive procedures. As a promising cancer marker,
telomerase activity has been assessed by using the TRAP assay on specimens such as
blood (Broccoli et al., 1995; Counter et ah, 1995), fine-needle aspirates of the breast
(Sugino et al., 1996), thyroid (Aogi et ah, 1998), liver (Nakashio et al., 1997), cervical
smears (Zheng et al., 1997), lung and oral washes (Califano et al., 1996; Aral et al.,
1998), pleural effusions (Yang et al., 1998), colonic luminal washings (Yoshida et al.,
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1997a), and urine (Kinoshita et al., 1997;Yoshida et al., 1997b). The results have proved
that the TRAP assay is sufficiently sensitive to detect telomerase activity in specimens
with a small number of cancerous cells.
Other experiments further confirm that the presence of telomerase activity in
tumors, at least some kinds of tumors, is associated with clinical outcome. Therefore,
telomerase activity can be considered as a prognosis indicator. For example, the presence
of telomerase activity suggests poor prognosis in gastric cancer, and the levels of activity
are correlated with tumor size, metastases, and survival (Tahara et al., 1996; Hiyama et
al., 1995). Other evidence also indicates that high telomerase activity is relatively
associated with poor prognosis in leukemias (Norrback et al., 1996; Zhang et al., 1996),
meningiomas (Langford et al., 1997), and breast cancers (Sugino et al., 1996; Hiyama et
al., 1996; Hoos et al., 1998). However, more studies are required to confirm the
relationship between telomerase activity and the prognosis of cancers.
Another important clinical application of telomerase activity measurements is to
monitor tumor burden in patients undergoing therapeutic regimens. The fact that
telomerase activity has been shown to mirror the clinical effects of chemotherapy in
breast cancers and leukemia (Hoos et al., 1998; Engelhardt et al., 1998) makes it a
convenient marker for repeated analysis in mini- or non-invasively obtained specimens.
3.

Telomerase as a Target for Anti-cancer Therapy

The clinical objective of anti-cancer therapy is to achieve a high therapeutic index.
With the knowledge of human telomeres and telomerase, it is clear that reactivation of
telomerase may be a necessary step for cell immortalization and for carcinogenesis in
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most instances. Since telomerase activity is absent in most human normal cells,
inhibition of this enzyme should lead to resumption of telomere shortening and might
activate the cellular senescence pathway in cancerous cells with minimal damage to
normal cells or the whole patient. Telomerase may therefore be an ideal target for anti
cancer therapy.
There are several strategies being developed now. First of all, oligonucleotidebased gene therapy has the advantage of being highly specific; consequently the selective
removal of an essential molecule from a particular pathway can be accomplished.
Designed antisense oligonucleotides have been found to pair with the RNA subunit of
human telomerase (hTR), preventing active telomerase complex formation between the
protein components and hTR, thus inhibiting telomerase activity successfully in cell lines
(Hamilton et al., 1997) and in a xenograft human/nude mouse model (Mata et al., 1997).
Antisense oligonucleotides for the promotor regions of the hTERT or the hTR gene could
be designed as a further potential therapeutic stratagem. Second, the initial studies on the
role of human chromosome 3 (Mehle et al., 1998; Tanaka et al., 1998; Vieten et al., 1998;
Cuthbert et al., 1999) indicate that reintroduction of a normal chromosome 3 into cancer
cells might be an effective way to inhibit telomerase activity and to restore cellular
senescence. Third, increasing knowledge of telomerase regulation may lead to the
identification of more potential targets for therapeutic intervention. For example, over
expression of the survival factor Bcl-2 can stimulate telomerase activity in human cancer
cells. Therefore, the regulation of endogenous Bcl-2 expression is tightly linked with
telomerase activity in a cultured T-cell line (Mandal and Kumar, 1997). The same idea
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can be applied to the proteins c-Myc, PKCa, PP2A, etc. It has been recently observed
that the expression of cyclin-dependent kinase inhibitor p21 WAF1 in immortalized
keratinocytes results in telomerase inhibition and growth arrest with down-regulation of
hTR expression (Kallassy et ah, 1998). Finally, a number of synthetic drugs that inhibit
cell proliferation, such as azidothymidine (AZT) (Melana et ah, 1998), quinolones
(Yamakuchi et ah, 1997), and cisplatin (Burger et ah, 1997), have been shown to function
in telomerase inhibition with concomitant growth arrest, even though the exact
mechanism is still unclear.
The contradiction still remains that telomerase is active in human germ line cells,
hematopoietic progenitor cells, and the proliferative cells of renewal tissues. Therefore,
the side-effects of telomerase inhibition therapy on these cells need to be evaluated. We
could argue that the activity in those cells is relatively low and that most cancer cells have
shorter telomeres combined with higher proliferation rates than normal replicative cell
populations, suggesting that telomerase inhibition therapy may cause cancer cell death
well before damage to regenerative tissues occurs. However, another problem surfaces
that there is a variability of telomere lengths among cancers. Telomerase inhibition
might be effective only in malignant cells with short telomeres, while cancer cells with
long telomeres would require a prolonged treatment, with possible toxic side-effects. It
should be also considered that the ALT mechanism, in addition to telomerase, may exist
for regulating telomere length in some telomerase-positive cancer cells. Also, some
human cancers, in which the ALT mechanism is the main mechanism for regulating
telomere length, show negative or weak telomerase activity. Telomerase inhibition
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therapy alone in these cases might not be curative, but it could halt the progression of the
more aggressive cancers and, in combination with other therapies, may buy the patient
and the clinician valuable time.

D.

THE HUMAN PROSTATE GLAND AND PROSTATE CANCER
1.

Normal Anatomy and Function of the Human Prostate Gland

The human prostate gland in males, located in the pelvis and lying between the
urinary bladder and the external urethral sphincter, consists of an epithelium-lined ductal
system embedded in a matrix of stroma (McNeal, 1988) (Figure 1.8A). The adult
prostate gland is about the size and shape of a large chestnut and weighs about 20 grams.
The prostate gradually increases in size and weight from the time of birth to the third
decade of life, when it reaches its normal adult size and weight, then keeps constant until
around age 45, at which time benign prostatic hyperplasia (BPH), a common condition
that causes bladder outlet obstruction, commences in most men. The growth of the
prostate gland from this age will continue very slowly until death.
Human prostatic tissue contains many small glands (Figure 1.8B), and each of
them pours the secretion from the epithelial cells into one of the prostatic ducts during
orgasm and ejaculation. These ducts in turn empty into the prostatic urethra. The ducts
that carry the spermatozoa and the fluid from the seminal vesicles, called the ejaculatory
ducts, also empty into the prostatic urethra. The fluid from the seminal vesicles serves as
a nutrient for the spermatozoa, while the spermatozoa, made in the testis, stored and
matured in the epididymis, are transported into the ejaculatory ducts via the vas deferens.
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During orgasm, spermatozoa, fluid from the seminal vesicles, and secretions from the
prostate gland, called prostatic fluid (PF), are all squeezed into the prostatic urethra
because of contractions of the muscles of the prostate and the seminal vesicles. This
mixture of fluids is then propelled to the outside during ejaculation by the spasmodic
contractions of the muscles that surround the urethra.
Zonal anatomy of human prostate describes three zones, the transition zone (TZ),
the central zone (CZ), and the peripheral zone (PZ) (McNeal, 1968) (Figure 1.8C). The
PZ comprises approximately 65% of the prostatic volume compared with about 25% for
the CZ and 5-10% for the TZ. Although it is hard to perceive the histological distinctions
among the zones in normal human prostate, these zones have great clinical significance in
terms of the development of both BPH and prostate cancer (PCa), e.g. BPH primarily
arises from the TZ, while more than 70% of carcinomas occur in the PZ.
The prostate is functionally considered to be an accessory sex gland for two
reasons. First, it is an accessory part of the sexual or reproductive tract because it is only
indirectly involved in procreation compared with the primary sexual structures, such as
the testes and the penis. Second, the prostate is a gland because it makes PF, which
primarily serves as a vehicle for the spermatozoa and secondarily provides some
nourishment to the spermatozoa. Since PF finally goes to the outside of the body during
ejaculation, the prostate is known as an externally secreting gland. PF secreted from the
acinar cells of the prostate gland is a homogeneous, serous and slightly acidic (pFt 6.6)
milky fluid with low (<1%) protein content. It constitutes nearly 0.5 ml of average 3-3.5
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ml of the normal human ejaculate. The constituents of prostatic secretion include various
enzymes, lipids, metal ions and amines (Kumar and Majumder, 1995).
2.

Human Prostate Cancer

Prostate cancer (PCa) is the most common noncutaneous malignancy in men
causing cancer-related deaths in the United States, second only to lung cancer in males.
The annual incidence during the 1990's has nearly tripled. It has been estimated that
almost 400,000 new cases of prostate cancer were diagnosed and more than 40,000 deaths
due to prostate cancer occured in the United States in 1996 (Parker et ah, 1996). In 1998,
new cases were decreased to 184,500 in the States because of the use of improved
diagnostic techniques, which reduces false positives. Nevertheless, about 40,000 deaths
still occurred (Landis et ah, 1998). Although prostate cancer is epidemiologically rare
among men under 50, it becomes more prevalent with age. Data from autopsies indicate
that approximately 70% of 80-year-old men have prostate cancer (Naitoh, 1998). Since
the U.S. contains an aging population, the problem is increasing. Fortunately, the
prognosis for those who develop prostate cancer has improved in recent years. The last
decade has seen dramatic advances made in the diagnosis and treatment of prostate
cancer.
Histopathologically, human prostatic tissue can be classified into three categories,
normal tissue, premalignant lesions, and carcinoma, depending on both histological
(pattern of acini under low magnification) and cytologic (morphology of the individual
cell under high magnification) criteria. Premalignant lesions diagnosed by fine-needle
biopsies include atypical adenomatous hyperplasia (AAH) and prostatic intraepithelial
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neoplasia (PIN), which can be further divided into low and high grades. AAH, which
may fulfill the histological criteria for malignancy but lacks the cytologic criteria, is
defined as a proliferation of microglandular structures that are insufficient for the
diagnosis of well-differentiated adenocarcinoma (Bostwick et ah, 1993). On the other
hand, PIN is defined as the presence of atypical or dysplastic epithelial cells within
benign-appearing glands and acini, which may fulfill the cytologic criteria without
satisfying the histological criteria (McNeal and Bostwick., 1986). PIN has been proven
to act as a precursor of carcinoma. Prostatic adenocarcinoma, which arises in the acinar
and proximal ductal epithelium and makes up over 95% of prostatic cancers (Trump et
al., 1997), fulfills both histological and cytologic criteria and is evaluated by a grading
system, termed the Gleason grading system. This system was the result of a Veterans
Administration Cooperative Urologic Research Group study that followed 4,000 patients
for about 15 years (Gleason and Mellinger, 1974; Gleason, 1977 & 1988). This system
bases the pathologists’ identification on low power patterns of glandular growth and
stromal infiltration and is divided into five grades. The system assigns a score that is the
sum of the two most dominant grades, irrespective of the cytology, resulting in a score of
2 to 10. In use, prostate cancers are commonly grouped into well differentiated (2-4),
moderately differentiated (5-7), and poorly differentiated (8-10) categories. Therefore,
the Gleason score offers valuable information about the prognosis as well as the cancer
volume of the patient (McNeal, 1992).
It is clinically reasonable to search for prostate cancer in the male patient who is
having difficulty voiding (slow stream, urgency) or hematuria, or who has signs and
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symptoms of metastatic cancer (bone spread resulting in an elevated alkaline phosphatase
level and progressive back pain, sciatica or lower extremity neurologic impairment).
However, most PCa patients do not have any signs and symptoms in the early stage
because carcinomas usually occur in the PZ of the prostate. It is believed that the early
detection of prostate cancer increases the probability of successful treatment (Von
Eschenbach et al., 1997). Therefore, the American Cancer Society and the American
Urological Association recommend that prostate cancer screening should be annually
performed in the suspected population, including all African-American men, men over
age 40 who have a family history of PCa, and all other men over age 50. However, this
recommendation has not been accepted by the American Academy of Family Physicians
and the U.S. Preventive Services Task Force (Naitoh et al., 1998).
Routine screening techniques include the digital rectal examination (DRE) and the
serum prostate specific antigen (PSA) test. DRE is the most practical diagnostic method
based on a physician’s experience but is less sensitive and specific. It has been reported
that more than 50% of prostate cancers diagnosed by DRE have already spread locally or
have metastasized to lymph nodes or bone (Naitoh et al., 1998), and only one third of the
firm palpable nodules revealed by DRE are histologically considered prostate cancer
(Catalona, 1980). The discovery of PSA and further serum PSA testing promoted the
screening tools to a new level. PSA is a 34 kDa glycoprotein secreted by several
epithelial cells and cancerous cells, including prostatic epithelium (Wang et al., 1979).
Serum PSA levels are proportional to either the total volume of prostate tissue or the
amount of irritation in the prostate, such as carcinoma or inflammation. Large screening
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trials have shown that PSA screening nearly doubles the rate of cancer detection (70% to
80%) compared to DRE alone (Catalona et ah, 1994). Based on these data, PSA, used as
a marker for PCa, has been approved by the U.S. Food and Drug administration (FDA)
for the screening and early detection of prostate cancer. Further research has revealed
that more advanced pathologic stages of PCa are always accompanied by higher serum
PSA levels (Stamey and Kabalin, 1989), and the serum PSA level is correlated with
tumor volume, and is an important predictor of tumor progression and prognosis (Ohori
et ah, 1994a & b). However, the specificity of the PSA test is quite low, because only
one third of men with an abnormal serum PSA level actually have cancer (Arcangeli et
ah, 1997). Test enhancements, including the free PSA test, the PSA velocity and density
test, PSA age-adjusted ranges, and the ratio of free PSA to bound PSA, have been further
developed for improving the test specificity. If abnormalities, in which the PSA level
rises more than 0.7 ng/ml per year or the contour of the prostate gland changes, are found
*

on the routine screening, patients should undergo further urologic evaluation with more
diagnostic techniques, e.g. transrectal ultrasound examination (TRUS), TRUS-guided
prostate biopsy or needle biopsy, computed tomography (CT), and/or magnetic resonance
imaging (MRI).
With the information from both clinical and pathological diagnosis, PCa needs to
be staged before a proper treatment can be performed. A new TNM staging system has
been clinically used instead of the old Whitmore-Jewett (ABCD) system since 1992.
Treatment decisions are usually made based on not only the stage of PCa but also the
side-effects, long-term risks, financial and emotional costs of the different therapies. In
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principle, the treatment options for organ-confined PCa include radical prostatectomy,
radiotherapy, and watchful waiting. Hormonal therapy, including testicular androgen
suppression and total androgen deprivation, may be a good option for the management of
metastatic cancer, whereas chemotherapy, including cytotoxic chemotherapy, the use of
estrogen analogs, and growth factor inhibitors may play a role in the management of
hormone-escaped PCa.

E.

RESEARCH OBJECTIVES
The first goal of this work was to determine the telomerase activity in prostatic

tissues obtained by needle biopsy. The fresh sextant needle biopsies from radical
retropubic prostatectomy (RRP) specimens were collected and extracted by a cell lysis
method, CHAPS protein extraction. The extracts were further tested by a PCR-based
TRAP assay. The results were statistically analyzed, and additional clinical and
pathological data were required in the process.
The diagnosis of cancer is better achieved in specimens obtained by non-invasive
procedures. Compared to prostatic tissue specimens, the prostatic secretion specimens,
such as prostatic fluid in urine (PFU) or prostatic fluid (PF) specimens, are collected
more easily. The second goal of our work was to detect telomerase activity in the
prostatic secretion specimens by using the TRAP assay. A few collection methods and
pretreatment procedures for the PFU and PF specimens were developed and evaluated by
the assay results. Additional clinical and pathological data were also subjected to further
statistical analysis.
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Recently, new telomerase PCR ELISA kits have been developed by Boehringer
Mannheim Co. and other companies. The advantages of the telomerase PCR-ELISA
method, namely, comparable sensitivity without the risk of using radioisotopes, a
relatively quick result delivery, and ease of use, make it a promising candidate for clinical
application. Therefore, the final goal of our work was to evaluate the clinical application
of the PCR ELISA kit by analyzing the telomerase activity in clinical specimens,
including prostatic tissue and prostatic secretion specimens. In the process, the
radioisotope-requiring TRAP assay was also performed in parallel with the ELIS A-based
assay.
In summary, the sensitive PCR-based TRAP assay, including the radioisotoperequiring method and the ELISA method, was extended and/or refined to determine the
telomerase activity in prostatic secretions and prostate needle biopsy specimens of
patients with or without prostate cancer. This research evaluated the role of telomerase in
the development, the diagnosis, and the prognosis of prostate cancer. Therefore, the
specific aims of this thesis were to:
A.

Determine the telomerase activity in prostate needle biopsy specimens.

B.

Detect the telomerase activity in prostatic secretion specimens.

C.

Use the telomerase PCR ELISA kit to analyze telomerase activity in
clinical specimens, including prostatic tissue and prostatic secretion
specimens, and correlate the results with those from the radioisotoperequiring TRAP assay.
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II. MATERIALS AND METHODS

A.

MATERIALS
Nylon disposable filter systems, cryogenic vials, and Kontes pellet pestles were

obtained from Fisher Scientific (Tustin, CA). Trypsin-EDTA and new-born calf serum
were purchased from GIBCO BRL (Grand Island, NY). RPMI 1640, L-glutamine,
penicillin, and streptomycin were from Mediatech, Inc. (Washington, DC). The human
prostate cancer cell line PC-3 was from the ATCC (Rockville, MD). Microeppendorf or
PCR tubes (thin-wall, 0.5 ml) were from USA Scientific, Inc. (Ocala, FL). AmpliWax
PCR Gem 50 was obtained from Perkin Elmer Biosystems (Foster, CA). Taq polymerase
was purchased from Sigma Chemical Co. (St. Louis, MO) and Promega Corp. (Madison,
WI). dNTPs were from Invitrogen (Carlsbad, CA). Stabilized [a-32P] dCTP was
purchased from ICN Biomedicals, Inc. (Irvine, CA). DNA oligonucleotide primers were
ordered from the Center for Molecular Biology and Gene Therapy of Loma Linda
University. The Molecular Imager system with Molecular Analyst software and screen
guard films were from Bio-Rad Laboratory (Hercules, CA). Fuji X-ray films and thick
filter papers were from Fisher Scientific (Tustin, CA) also. Telomerase PCR ELISA kits
were from Boehringer Mannheim (Indianapolis, IN). RNase A, BSA, and all other
chemicals were molecular biology grade and were from Sigma Chemical Co. (St. Louis,
MO) or Fisher Scientific (Tustin, CA).
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B.

METHODS

1.

Cell Culture
a.

Cell Growth and Maintenance

PC-3 cells, with a doubling time of 2.7 days in tissue culture (Kaighn et ah, 1979),
were grown in complete RPMI 1640 media (RPMI supplemented with 10% new-born
calf serum, 2 mM L-glutamine, 100 U of penicillin per ml, and 100 pg of streptomycin
per ml). The cells were cultured at 37 °C in a water-saturated atmosphere containing 5%

co2.
b.

Preparation of Culture Medium

Supplements were added to the RPMI medium prior to use. Complete RPMI
medium was prepared in 0.5 liter batches and stored at 4°C. Serum was heat inactivated
at 50 °C for 45-60 min. This serum was then either used directly or frozen at -20 °C in 10
ml aliquots. Other medium components were prepared as 100 x solutions and frozen at
-20 °C in 10 ml aliquots.
c.

Freezing and Thawing Cells

Medium for freezing cells, containing 10% new-born calf serum, 10% DMSO,
and 80% RPMI, was made up in advance and stored at -20 °C until use. Small aliquots of
cell cultures were used to obtain a cell count using a hemocytometer, but the bulk was
transferred to a sterile 15 ml polypropylene tube and centrifuged at 3,000 rpm for 5 min
at room temperature in a Beckman table-top centrifuge. The cell pellet was resuspended
in the freezing medium to a cell concentration of 5 x 106 cells/ml. One milliliter
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quantities were transferred to plastic cryogenic vials and frozen at -70 °C overnight. The
vials were then transferred to liquid nitrogen for long-term storage.
To thaw the cells, a vial was transferred quickly from -196 °C to 37 °C. The
freezing mixture was diluted out slowly to a total volume of 15 ml by adding warm
complete medium dropwise over 1-2 min. The cell suspension was then transferred to a
sterile 15 ml polypropylene tube and centrifuged at 3,000 rpm for 5 min at room
temperature in a Beckman table-top centrifuge. The cell pellet was resuspended in 7-15
ml of complete medium and transferred to a small flask for growth overnight.
d.

Counting Cells and Determining Cell Viability

Total cell count and determination of cell viability were done using a Neubauer
hemocytometer (Fisher Scientific Co.) and a PhotoZoom Inverted Microscope
(Cambridge Instruments). For total cell count, 10 pi of cell suspension from a culture
flask was loaded onto the hemocytometer. The cells were counted in each of 5 grids and
the total number of cells/ml (N) calculated as: N = (Total number of cells in 5 grids/5) x
104.
Viability counts were done in a similar manner using the dye exclusion test. A 10
pi aliquot of cell suspension was added to an equal volume of trypan blue (0.4% in H20,
filtered through 0.45 pm filter), mixed, and left for 1-2 min. The total number of cells
unstained and stained were counted using the hemocytometer. The total number of
cells/ml (T) was calculated as: T = (Total number of cells in 5 grids/5) x 2 x 104. Percent
viability (V) was calculated as: V = (Number of cells unstained/Total number of cells) x
100%.
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e.

Subculturing Cells

When the cells had grown almost to confluence, they were either harvested as a
whole or distributed into several new flasks. In brief, the medium in the original flask
was removed, the bottom of flask was rinsed gently with 3-4 ml of phosphate-buffered
saline, then 3-4 ml of 0.05% trypsin-EDTA was added into the flask and the latter was
incubated at 37 °C for 5 min. When the cells were dispersed or suspended, as observed
microscopically, the cell suspension was transferred to a sterile 15 ml polypropylene tube
containing 6-7 ml of complete medium and centrifuged at 3,000 rpm for 5 min at 4°C.
The cell pellet was resuspended in 15 ml of complete medium and transferred to three
flasks for further growth.
f.

CHAPS Extraction of Cells

The cells were harvested when 90% confluent using trypsin. After the cells were
collected by centrifugation at 3,000 rpm for 5 min at 4°C, the cell pellet was washed
twice with 5 ml of cold phosphate-buffered saline, resuspended in ice-cold Buffer A [10
mM HEPES-KOH (pH 7.5), 1.5 mM MgCl2> 10 mM KC1, 1 mM dithiothreitol] at 106
cells per 100 pi, and recentrifuged at 4,000 rpm for 5 min at 4 °C. The cell pellet was
lysed in Buffer B (Lysis Buffer) [0.5% 3-(3-cholamidopropyl-dimethylammonio)-lpropanesulfonate (CHAPS), 5 mM f3-mercaptoethanol, 0.1 mM phenylmethanesulfonyl
fluoride (PMSF), 10% glycerol, 10 mM Tris-HCl (pH 7.5), 1 mM MgCl2] at 106 cells per
20 pi for 30 min on ice. Then, the lysate was centrifuged at 16,000 x g for 20 min at 4
°C. Aliquots of the supernatant fluid were immediately stored at -80 °C. The protein
concentration was determined by ultraviolet spectrophotometry (Robyt and White, 1990).
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2.

Serum Albumin Ultraviolet Absorbance Standard Curve
Proteins have a characteristic absorption around 275-280 nm due to the presence

of tyrosine and tryptophan residues. Absorbance measurements at 280 nm are frequently
used to obtain the protein concentration. This method is relatively fast, easy to be
handled, nondestructive, and reasonably sensitive even though it is not very specific.
A standard curve of the absorbance at 280 nm (A28o) was obtained with bovine
serum albumin solutions of varying concentrations. The slope, which was 0.6575 (A280 x
pl/pg protein), was determined after a plot of A280 against BSA concentration. Therefore,
protein concentration (pg/pl) = A280/0.6575.
3.

Fresh Prostatic Tissue Specimens
a.

Collection of Sextant Needle Biopsies from Radical Retropubic
Prostatectomy (RRP) Specimens

A total of 327 prostate needle biopsy specimens were collected from 56 patients
in the operating room. These included 291 specimens from 45 PCa patients, 18
specimens from 3 patients without PCa but with local invasion of the bladder by
transitional cell carcinoma (TCC), and 18 specimens from 8 patients with no evidence of
PCa or other kinds of cancer. Using 18-gauge cutting needles (C.R. Bard, Inc.,
Covington, GA) from a Biopty gun, needle cores were mainly obtained from six regions
and from an occasional nodule of the posterior prostate once the prostate was removed by
RRP (Figure 2.1). For further pathological examination, dye (Bradley Products, Inc.,
Bloomington, MN) colored green, red or yellow was applied for marking the areas where
the needle cores were taken. The needle cores were kept on ice until they could be frozen
at -80 °C, usually within 30 minutes after collection.
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Figure 2.1. Six regions of the prostate in posterior coronal plane. Needle cores were
basically obtained from these six regions for the detection of telomerase activity. RB =
right base; RM = right mid-section; RA = right apex; LB = left base; LM = left mid
section; LA = left apex. (Modified from “The prostate book: sound advice on symptoms
and treatment” edited by S. N. Rous in 1992.)
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b.

Preparation of CHAPS Extracts from the Needle Biopsy Cores

The frozen biopsied needle core was soaked in a 5x volume/weight of lysis buffer
and homogenized on ice in a Kontes tube with a matching pestle, then extracted as
described for the PCS cells. The protein concentration was determined by ultraviolet
spectrophotometry (Robyt and White, 1990) based on the standard curve for serum
albumin. Aliquots were frozen at -80 °C until assayed.
4.

Prostatic Secretion Specimens
a.

Collection of Prostatic Fluid-in-Urine (PFU) with Added Protease
Inhibitors

Specimens were obtained from 15 men seen as inpatients at the Loma Linda
University Medical Center. Among these, 5 subjects had clinician- and pathologistconfirmed prostate cancer (PCa) but no other kind of cancer, 5 patients were diagnosed as
having symptomatic benign prostatic hyperplasia (BPH) but no clinical evidence of PCa,
and the remaining 5 patients had no PCa, other kinds of cancer, or BPH symptoms.
Following digital massage of the prostate gland, 30 ml of voided urine from each patient
was collected in a siliconized plastic tube that contained several protease inhibitors, the
final concentrations of which were 10 mM disodium EDTA, 5 mM benzamidine HC1
(BZA), 20 mM caproic acid, and 0.2 mM PMSF. The specimen was then centrifuged
(1,200 x g) for 10 min at 4°C. Aliquots of the supernatant fluid were immediately stored
at -80 °C.
b.

Collection of Prostatic Fluid without Added Protease Inhibitors (PF1)

PF1 specimens were obtained from 18 patients who were diagnosed with prostate
cancer. A limited volume of prostatic fluid was expressed and collected at the prostatic
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apex by vigorous massage of a radical prostatectomy specimen immediately after
resection. In order to assess the stability of telomerase in prostatic fluid, no protease
inhibitors were added to any samples. An aliquot of each specimen was stored at -80 °C
after snap freezing in liquid nitrogen. The rest of the specimen was centrifuged (1,200 x
g) for 10 min at 4 °C. Aliquots of the supernatant fluid were stored at -80 °C. The
proteins present in the pellet were extracted by the CHAPS extraction method as
described above. Aliquots of the CHAPS extract were also stored at -80 °C. The
collection process took between 2-4 h for each sample. The protein concentrations of the
CHAPS extracts were determined by ultraviolet spectrophotometry.
c.

Collection of Prostatic Fluid with Added Protease Inhibitors (PF2)

The stability of telomerase in prostatic fluid was further explored by collecting
specimens from 30 additional PCa patients. Specimens were also obtained from 9
patients clinically confirmed as cancer-free, including 6 BPH patients. In brief,
siliconized microcentrifuge tubes were prepared in advance to contain 1.18 ml of a master
mix of protease inhibitors (see below). A few minutes prior to specimen collection, 20 pi
of an ethanol solution of PMSF, which was made by dissolving a quantity of PMSF in
95% ethanol (2.613 mg/ml) and stored in a brown microeppendorf tube at 4°C, was
added to each microcentrifuge tube. The prostatic fluid was obtained by prostatic
massage performed on patients about to undergo radical prostatectomy. Approximately
300 pi of prostatic fluid from each patient was collected by palpating the prostate and
milking the fluid through the urethra, pipetting the specimen immediately into the
micro tube, and mixing it with the protease inhibitors by inversion three times. The final
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concentrations of the protease inhibitors were 10 mM disodium EDTA, 5 mM BZA, 20
mM sodium caproate, and 0.2 mM PMSF. The microtube was then centrifuged (2,500 x
g) for 5 min in an Eppendorf table-top centrifuge at 4 °C. The supernatant fluid was
divided into aliquots, which together with the pellet were placed on dry ice and
transferred to the laboratory. The aliquots of the supernatant fluid were stored at -80 °C
for the coming assay, while the pellet was further treated by the CHAPS extraction
method as described above. This extract was also divided into aliquots for freezing and
storage at -80 °C. The collection process took 1-2 h for each sample. The protein
concentrations of the CHAPS extracts were determined by ultraviolet spectrophotometry.
A master mix of protease inhibitor solution was made according to the following
protocol. In brief, 41.4 mg of sodium caproate was dissolved in a few milliliters of
DEPC-treated distilled H20 and mixed with 300 pi of 0.5 M disodium EDTA (pH 8.0) in
a sterile 15 ml polypropylene tube. A fresh solution of BZA was also made separately by
dissolving 59.0 mg of crystal BZA in 1 ml of 95% ethanol. 200 pi of fresh BZA solution
was added into a mixed solution of sodium caproate and disodium EDTA, DEPC-treated
distilled H20 was then added to a total 11.8 ml volume. After a complete mixing, 1.18
ml aliquot of this solution was pipetted into 9 siliconized 2 ml plastic microcentrifuge
tubes, which were kept at 4 °C subsequently.
5.

The Radioisotope-requiring TRAP Assay
For the needle cores, aliquots of the CHAPS extract (6, and/or 0.6 pg protein)

were used in the TRAP assay. In some cases, an aliquot of the CHAPS extract from each
specimen (6 or 0.6 pg protein) was pretreated with RNase A (0.2 pg/pl at 37 °C for 30
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min) as a telomerase-specific negative control before it was used for the assay. For the
other cases, serial dilutions of the CHAPS extract from a specimen (6 and 0.6 pg protein)
were made to guard against possible false negative results.
In the PFU group, aliquots (5 pi and 1 pi) of the supernatant fluid from each
patient were used for the TRAP assay. Each aliquot was assayed in duplicate. Three
different aliquots [supernatant fluid, CHAPS extract of the pellet (6 pg protein), and/or
whole prostatic fluid] were used for the TRAP assay of PF1, while two different aliquots
[supernatant fluid and CHAPS extract of the pellet (6 pg protein)] were used for the assay
of PF2. Some of the aliquots from each specimen were also pretreated with heat (85 °C
for 15 min) or RNase A (0.2 pg/pl at 37 °C for 30 min) before they were used in the
assay.
Aliquots of the CHAPS extract corresponding to approximately 3,000 PC-3 cells,
containing 6 pg protein, were assayed as a positive control, or as a negative control by
inactivating the extract with heat (85 °C for 15 min) or RNase A (0.2 pg/pl at 37 °C for
30 min). To standardize the telomerase activity and estimate how much telomerase was
present in each specimen, aliquots of PC-3 cell extracts corresponding to 3,000, 300, 30,
and 3 cells for the needle cores and 1,000, 100, 10, and 1 cell for prostatic secretion
specimens were also assayed.
The TRAP assay for telomerase activity was performed as described (Kim et ah,
1994) with minor modifications (Figure 2.2). In brief, an appropriate aliquot of either a
prostatic specimen, including tissue and secretion, or the CHAPS extract of PC-3 cells
was assayed in 50 pi of reaction mixture containing 50 pM dNTPs, 0.1 pg of TS primer
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Figure 2.2. The radioisotope-requiring TRAP assay. Step 1, aliquot of CHAPS
extracts or original clinical specimen is mixed with TRAP buffer, dNTPs, forward TS
primer, Taq polymerase, and [a-32P] dCTP to be a reaction cocktail. Step 2, telomerase
reaction. Telomerase, if present, adds multiple 6-nucleotide telomeric repeats to forward
TS primer by reverse transcription followed by a PCR amplification (Step 3). Step 4, the
PCR product is then run on a nondenaturing polyacrylamide gel, dried, and exposed to Xray film, or developed in a Molecular Imager system (Step 5). Typical products of
telomerase activity are shown by the 6-bp ladder bands starting from 40 bp.
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(5'-AATCCGTCGAGCAGAGTT-3'), 2 Units of Taq polymerase, 1 pi of [a-32P]dCTP
(10 mCi/ml, 3,000 Ci/mmol), 20 mM Tris-HCl (pH 8.3), 1.5 mM MgCl2, 63 mM KC1, 1
mM EGTA, 0.005% Tween-20, and an aliquot of supernatant fluid, whole prostatic fluid,
or CHAPS extract, including the extract from either needle core tissue, or the pellet of
prostatic fluid, or PC-3 cells, in a 0.5 ml tube that contained 0.1 pg of CX primer (5'CCCTTACCCTTACCCTTACCCTAA-3') sequestered at the bottom of the 0.5 ml tube
by a wax barrier (Ampliwax, Perkin Elmer, Foster city, CA). After a period (30 min in
testing needle core specimens and 45 min in testing prostatic secretion specimens) of
incubation at room temperature, the reaction mixture was subjected to 30 PCR cycles for
the needle cores or 34 PCR cycles for prostatic secretion specimens, consisting of 94 °C
for 30 s, 50 °C for 30 s, and 72 °C for 90 s. The PCR product was then subjected to
electrophoresis on a 10% nondenaturing polyacrylamide gel, dried, and exposed to X-ray
film, or developed in a Bio-Rad Molecular Imager in conjunction with the Molecular
Analyst software (Bio-Rad Laboratories, Hercules, CA). Typical products of telomerase
activity were shown by the 6-bp ladder bands starting from 40 bp. Telomerase activity
was graded on a scale of (-) to (+++) {(-), negative; (+++), strong positive}. The
following standards were used to judge a sample telomerase positive: (1) the presence in
a sample lane of more than four bands of the 6-bp telomerase repeat, which could be
eliminated by either RNase A or heat, and (2) repetition of the result with two or more
replicate samplings. For a semi-quantitative assay, the lane was scanned by using a BioRad Molecular Imager in conjunction with the Molecular Analyst software, and all of
peaks found were summed to yield a net incorporation per assay, which minus its own
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background created a mean density per assay. If the activity in 0.6 pg protein of PC-3
cell extract equivalent to 300 cells was defined as 100 units, a relative activity (Unit) in a
specimen could be expressed after its mean density from the assay was normalized to the
PC-3 standard curve (Figure 2.3). A semi-log standard curve was set up for each
experiment.
6.

The Telomerase PCR-ELISA Method
The telomerase PCR-ELISA, developed by Boehringer Mannheim, is an

adaptation of the conventional TRAP assay (Kim et al., 1994). It allows highly specific
amplification of telomerase-mediated extension products combined with nonradioactive
detection following an ELISA protocol (Figure 2.4). Compared to the conventional
assay, this new PCR-ELISA contains all compounds required for the telomerase reaction
and PCR in a ready-to-use reaction mixture for combining both reactions in a onestep/one-tube-reaction. Furthermore, the use of optimized primer sequences in the new
assay eliminates the need for separation of the primers by a wax barrier, and avoids
amplification artifacts, such as primer dimers.
For each sample to be tested, 25 pi of ready-to-use reaction mixture was
transferred into a 0.5 ml tube (thin-wall) on ice. It was mixed with an aliquot (Ipl) of the
clinical specimen described above and an extra 24 pi of DEPC-treated H20. The tube
was then transferred to a PCR thermal cycler to perform a combined primer extension or
elongation/amplification reaction, wherein telomerase adds telomeric repeats (TTAGGG)
to the 3' end of the biotin-labeled synthetic Pl-TS-Primer, and elongated products are
further amplified by PCR using the primers Pl-TS and P2, generating PCR products with
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Figure 2.4. Principle of the telomerase PCR ELISA for detection of telomerase
activity. Step 1, telomerase, if present, adds multiple 6-nucleotide telomeric repeats to a
biotinylated synthetic primer. Step 2, the telomerase reaction product is amplified by
PCR, using a biotinylated forward primer as above. Step 3, after denaturation, the singlestranded PCR product hybridizes to a digoxigenin (DIG)-labeled probe specific for the
telomeric repeat. Step 4, the DNA hybrid binds to a streptavidin-coated microtiter plate,
and anti-DIG-peroxidase and TMB substrate generate a colored product measurable with
a microtiter plate (ELISA) reader.
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the telomerase-specific 6 nucleotide increments. The protocol was 30 min at 25 °C for
primer elongation, 5 min at 94 °C for telomerase inactivation, and 30 PCR cycles
consisting of 94 °C for 30 s, 50 °C for 30 s, and 72 °C for 90 s, followed by 10 min at 72
°C.
The next step is the detection of products by ELISA. Briefly, 5 pi of the PCR
product was mixed with 20 pi of denaturation reagent and incubated at room temperature
for 10 min. The mixture was further mixed with 225 pi of hybridization buffer
containing a digoxigenin (DIG)-labeled, telomeric repeat-specific detection probe. The
resulting product (100 pi aliquot) was transferred into a well of the microtiter plate,
sealed and incubated at 37 °C on a shaker (200 rpm) for a few hours for immobilization
via the biotin labeled primer to a streptavidin-coated microtiter plate. The immobilized
PCR product was then detected with 100 pi of anti-DIG-POD working solution, which
contains an antibody against digoxigenin that is conjugated to peroxidase, after the well
was rinsed by washing buffer several times. After a period of reaction incubation at room
temperature on a shaker (200 rpm) and further rinsing of the wells with washing buffer a
few times, 100 pi of TMB substrate solution was added to the well and incubated for
color development, wherein the probe is visualized by virtue of peroxidation of TMB to
form a colored reaction product. The color development was terminated by adding 100
pi of stop reagent. The difference between the absorbances at 450 run and 655 nm (A450 A 655 or AA) was measured with a microtiter plate (ELISA) reader. In general, telomerase
activity in the needle core specimens was considered to be positive if the difference in
absorbance was >0.2, whereas the activity in prostatic secretion specimens was
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considered to be positive if the difference in absorbance was >0.1. For a semiquantitative analysis, the activity in 0.6 pg protein of CHAPS extract of PC-3 cells,
equivalent to the CHAPS extract from 300 PC-3 cells, was defined as 100 units. A
relative activity (Unit) in a specimen could be expressed after the difference in
absorbance (AA) from this specimen was normalized to the PC-3 standard curve (Figure
2.5). A semi-log standard curve was set up for each experiment.
7.

Statistical Analysis
Statistically significant differences and associations were evaluated by means of

the chi-square test (x2 test). P values <0.05 were considered statistically significant.
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III. APPLICATION OF THE TELOMERIC REPEAT
AMPLIFICATION PROTOCOL FOR DETECTION OF
CANCER IN PROSTATE NEEDLE BIOPSY SPECIMENS
A.

RESULTS
In agreement with previously reported data (Sommerfeld et al., 1996), substantial

telomerase activity was observed in lysates from PC-3 cells. Accordingly, CHAPS
extract of PC-3 cells and CHAPS lysis buffer were used in the TRAP assay as positive
and negative controls, respectively. Since telomerase activity could be eliminated by
RNase A (Greider and Blackburn, 1987; Morin, 1989), an aliquot of CHAPS extract pre
treated with RNase A was used as a specific negative control for telomerase activity in
the assay. In a serial dilution study of the PC-3 CHAPS lysate, telomerase activity could
be detected in a protein extract corresponding to as few as three PC-3 cells when using a
regular 30-PCR cycle (Figure 3.1, lanes 14-17), confirming the high sensitivity of the
assay system to detect telomerase activity in immortal cells. The results from this
dilution study were employed as a standard of comparison to evaluate the relative
telomerase activity in the clinical specimens.
Telomerase activity was detected in at least one needle biopsy specimen from 41
of 45 PCa patients (91%) {P <0.001), but was found in only 1 of 8 noncancerous patients
(12%) (P <0.001) (Table 3.1, Figures 3.1 & 3.2). The positive predictive value (PPV)
here approached 98%. All three patients (6 needle cores each) with local invasions of
bladder transitional cell carcinoma (TCC) showed positive telomerase activity in at least
one of the biopsy cores (data not shown), suggesting that positive activity also shows up
in regions of metastatic cancer from prostatic malignancy. For comparison, 210 of 291
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Table 3.1. Telomerase activity in prostate needle core tissues
Patient group
Prostate Carcinoma
Telomerase
Activity

Present

i

Specimen group 3
Total (n)

Absent

Present

Absent

Total (n)

Positive

41 O

1 ©

42

88©

28 0

116

Negative

40

7©

11

10©

102 0

112

Total (n)

45

8

53

98

130

228 2

Sensitivity (%)

Negative Predictive
Value (NPV) (%)

78
(102/130)

88
(7/8)

Specificity (%)
Positive Predictive
Value (PPV) (%)

90
(88/98)

91
(41/45)

76
(88/116)

98
(41/42)

91
(102/112)

64
(7/11)

i

Patients were clinically and pathologically diagnosed.
2 210 sextant needle cores from 35 PCa patients and 18 needle cores from patients without PCa or other
cancer-invasions were examined.
3 Presence or absence of cancer was determined by histopathological examination.
O, ©, ©, 0: significantly different from each other (P <0.001).
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Figure 3.1. Telomerase activity in sextant needle core specimens from a PCa patient
(I). Lanes 1 and 2, 3 and 4, 5 and 6, 7 and 8, 9 and 10, 11 and 12, CHAPS extract of
needle cores (0.6 pg protein) from RB, RM, RA, LB, LM, LA regions of prostate,
respectively; lanes 1, 3, 5, 7, 9, 11, CHAPS extract (0.6 pg protein) with RNase
pretreatment; lane 13, lysis buffer; lanes 14, 15, 16, 17, serial dilutions of CHAPS extract
of PC-3 cells, 3000, 300, 30, and 3 cell equivalents, respectively; lane 18, CHAPS extract
of PC-3 cells, 3000 cell equivalent, pre-treated with RNase A.
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9 10 11 12 13 14 15 16 17 18

Figure 3.2. Telomerase activity in sextant needle core specimens from a PCa patient
(II). Lanes 1 and 2, 3 and 4, 5 and 6, 7 and 8, 9 and 10, 11 and 12, needle cores from RB,
RM, RA, LB, LM, LA regions of prostate, respectively; lanes 1, 3, 5, 7, 9, 11, CHAPS
extract of needle core (0.6 pg protein); lanes 2, 4, 6, 8, 10, 12, CHAPS extract (6 pg
protein); lane 13, lysis buffer; lane 14, 15, CHAPS extract of PC-3 cells (0.6 pg protein),
without or with RNase pretreatment, respectively.
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sextant needle cores from 45 patients with prostate adenocarcinoma and 18 needle cores
from 8 noncancerous patients were subjected to histopathological examination. Eighty
eight of 98 specimens (90%) containing cancerous cells showed positive telomerase
activity {P <0.001), whereas 102 of 130 specimens (78%) without histologically
confirmed cancerous cells were telomerase negative (P <0.001). The overall positive
predictive value (PPV) was 76%, and the negative predictive value (NPV) was up to
91%, compared to 64% in group patients (Table 3.1, Figures 3.1 & 3.2).
In the histopathological examination, 24 (4 patients) of 210 sextant needle cores
from 35 PCa patients were subjected to multiple slide-cutting for each specimen. The
volumes of cancer on 80 slides were estimated. The volumes were compared with
relative telomerase activity in the needle cores from the same area (Table 3.2).
Interestingly, low cancer volumes on the slides from the needle cores were statistically
associated with relatively weak telomerase activity, while stronger activity was usually
found in the needle cores with high cancer volume. The statistically significant
correlation between telomerase activity and a given volume of cancer (P <0.05) suggested
that relative telomerase activity may indicate the volume of prostate carcinoma.
As indicated in “Materials and Methods”, needle core specimens were obtained
from six regions, namely, right base (RB), right midsection (RM), right apex (RA), left
base (LB), left midsection (LM), and left apex (LA), of the prostate gland (Figure 2.1).
Aliquots of CHAPS extracts of these sextant needle core specimens were eligible for
further TRAP assays. RNase pretreatment controls were needed as specific negative
controls of telomerase-assayed specimens (Figure 3.1, lanes 1, 3, 5, 7, 9, 11, and 18).
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Table 3.2. Comparison of telomerase activity with histopathologically determined
volume of cancer in prostate needle cores O
Relative Telomerase Activity
in Needle core

Volume Distribution of Cancer on the Slide
No Cancer Seen
<25%
25% - 50%
>50%

Total (n)

Negative (-)

10 (50%)

12 (38%)

4 (25%)

0 (0%)

26

Weak Positive (+)

6 (30%)

13 (41%)

7 (44%)

5(42%)

31

Positive (++)

4 (20%)

5 (16%)

3 (19%)

2 (17%)

14

Strong Positive (+++)

0 (0%)

2 (6%)

2 (13%)

5 (42%)

9

Total (n)

20

32

16

12

80

1 The number of slides exhibiting a given volume of cancer (% of total slides for each given volume);
O: high correlation shown between the relative telomerase activity and a given volume of cancer (x2 test, P
<0.05).
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Serial dilution of CHAPS extract was used to estimate relative telomerase activity in the
needle cores and to identify possible false-negative specimens (Figure 3.2, lanes 1-12 &
Figure 3.3, lanes 1-4). The data suggested that telomerase activity in sextant needle cores
indicates not only whether the prostate gland contains cancerous cells, but also the
possible cancer region and the volume of cancer. For example, the large cancer volumes
could be identified in both RA and RM regions of the prostate as in the case shown in
Figure 3.1. In the case of Figure 3.2, prostate carcinoma occurred mainly in the RA and
RM regions, with less in the RB and LA regions of the prostate. In this study, some
specimens gave unexpected assay results by showing detectable or relatively high
telomerase activity with a smaller aliquot (0.6 pg protein) whereas with a larger aliquot (6
pg protein), the telomerase activity was lower or not detectable (Figure 3.3, lanes 1-4).
These results suggested that possible Taq polymerase inhibitors in the tissue might cause
false-negative results and that a serial dilution assay could be an efficient way to
overcome the inhibitor effect. To search for possible chemical inhibitors of the TRAP
assay, we set up a mixing test in which serial dilutions of some dyes were mixed with
CHAPS extract (0.6 pg protein) of PC-3 cells before telomerase activity was assayed
(Figure 3.4A & B). Telomerase activity was completely inhibited by 80 x diluted green
dye (Figure 3.4A, lane 1) and by 2,560 x diluted red and yellow dyes (Figure 3.4A, lane
10 & Figure 3.4B, lane 1). The activity was partially inhibited by 160 x diluted green dye
(Figure 3.4A, lane 2), 5,120 x diluted red dye (Figure 3.4A, lane 11), and even by 10,240
x diluted yellow dye (Figure 3.4B, lane 2). The dilution studies showed that all three
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Figure 3.3. Inhibition of telomerase activity in needle core specimens from cancer
regions of the prostate gland. Lanes 1 and 2, 3 and 4, needle cores from RA, LB of a
prostate, the confirmed cancer regions, respectively; lanes 1, 3, CHAPS extract of needle
core (0.6 pg protein); lanes 2, 4, CHAPS extract (6 pg protein); lane 5, lysis buffer; lane
6, 7, CHAPS extract of PC-3 cells (0.6 pg protein), with or without RNase pretreatment,
respectively.
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Figure 3.4. Inhibition of telomerase activity in a CHAPS extract of PC-3 cells (0.6
Hg protein) by the addition of the dyes. A. Lanes 1-8, serial dilutions of green dye, 80,
160, 320, 640, 1280, 2560, 5120, 10240 time dilutions of original dye, respectively,
mixed with CHAPS extract of PC-3 cells (0.6 pg protein); lanes 9-12, serial dilutions of
red dye, 1280, 2580, 5120, 10240 time dilutions of original dye, respectively, mixed with
CHAPS extract of PC-3 cells (0.6 pg protein); lane 13, 14, CHAPS extract of PC-3 cells
(0.6 pg protein), with or without RNase pretreatment, respectively; lane 15, lysis buffer.
B. Lanes 1-3, serial dilutions of yellow dye, 2580, 5120, 10240 time dilutions of original
dye, respectively, mixed with CHAPS extract of PC-3 cells (0.6 pg protein); lane 4, 5,
CHAPS extract of PC-3 cells (0.6 pg protein), with or without RNase pretreatment,
respectively; lane 6, lysis buffer.
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dyes were able to inhibit the TRAP assay at low concentrations, and that the red and
yellow dyes were stronger inhibitors than the green dye.
The relationship between telomerase activity and Gleason score was also
examined. Twelve of 36 needle core specimens (33%) from patients with well
differentiated PCa (Gleason score of 2 to 4) had positive telomerase activity. Of 210
specimens from moderately differentiated cancers (Gleason score of 5 to 7), 116 (55%)
showed positive activity, while 19 of 24 specimens (79%) from poorly differentiated
cancers (Gleason score of 8 to 10) showed relatively strong activity (Table 3.3). The data
indicated that telomerase activity in needle cores was statistically correlated with the
Gleason score (P <0.01). From the data above, average positive needle cores per patient
in different Gleason score groups were calculated for 270 needle cores from 45 PCa
patients. One needle core on average showed positive telomerase activity in the score 2
group, 2.2 in the score 4 group, 2.7 in the score 5 group, 3.4 in the score 6 group, 3.6 in
the score 7 group, 4 in the score 8 group, and 5 in the score group 9 and 10. Furthermore,
average needle cores that showed positive activity in low-grade tumors were 2 (Gleason
score of 2 to 4), 3.3 in intermediate-grade tumors (Gleason score of 5 to 7), and 4.8 in
high-grade tumors (Gleason score of 8 to 10) (Figure 3.5). Thus the number of needle
cores with positive telomerase activity in sextant needle biopsy specimens increased with
higher Gleason scores.

B.

DISCUSSION
The development of diagnostic tools is important for the therapeutic evaluation of
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Table 3.3. Correlation of Gleason score with telomerase activity in needle core
specimens from PCa patients

Gleason Scores

No. of
Specimens
(Patients)

Positive

Telomerase Activity
Negative

Total (n)

2-4

12 0(5)

24(1)

36(6)

5-72

116 0(32)

94 (3)

210(35)

8 - 103

19 0(4)

5(0)

24 (4)

Total (n)

147 (41)

123 (4)

270 (45)4

1 well differentiated adenocarcinoma;
2 moderately differentiated adenocarcinoma;
3 poorly differentiated adenocarcinoma;
4 270 needle cores from 45 PCa patients were analyzed.
O: high correlation shown between telomerase activity and Gleason scores based on
information from needle core specimens (x2 test, P <0.01).
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prostate cancer patients. As a mini-invasive pathological technique, prostate needle core
biopsy has been well developed and is one of the most favored methods for obtaining
diagnostic material from the prostate gland (Renshaw and Corless, 1997). For diagnostic
and prognostic purposes, it is definitely valuable to examine telomerase activity in
prostate needle core tissue, which not only systematically evaluates the relationship
between telomerase activity and prostatic malignancy, but also should provide a basis for
setting up a new diagnostic system for the detection or early detection of prostate cancer.
In the present study, a highly sensitive PCR-based TRAP assay was set up and the
PC-3 human prostate cancer cell line was used as a positive standard together with a
negative RNase control. A serial dilution trial showed that the TRAP assay is sensitive
enough to detect telomerase activity in CHAPS extract from as few as three PC-3 cells,
confirming that it is a robust assay for clinical use.
The high percentages of sensitivity and specificity derived from the data of either
the patient group or specimen group (Table 3.1) indicated that telomerase activity is a
promising diagnostic marker for prostate cancer. A patient was scored as positive for
telomerase if at least one of the sextant needle biopsy specimens showed positive activity.
This definition may contribute to the finding that PPV was relatively higher than NPV in
the patient group compared to the specimen group. It could further infer that collecting
multiple needle biopsy specimens from six regions of the prostate gland increased the
probability to obtain the tumor tissue, to have positive telomerase activity for a patient.
One of the sextant needle cores from a high PIN patient among 8 noncancerous patients
showed weak positive telomerase activity, suggesting that this prostate contained a
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localized and pathologically undetected cancer (Zhang et ah, 1998). This result was
consistent with data previously published (Shay and Wright, 1996; Shay and Bacchetti,
1997) that telomerase activity could be detected in a lower percentage (14%) of
premalignant tumor tissues. Other groups have reported that telomerase is positive in
bladders with primary transitional cell carcinoma (TCC) (Lee et ah, 1998; Rabat et ah,
1999). Our initial data showed that telomerase activity could also be detected in prostates
with local invasion of TCC.
We found that 10% of histopathologically confirmed cancerous specimens were
telomerase negative, whereas 22% of histopathologically confirmed noncancerous
specimens showed positive activity. However, there may have been sampling
discrepancies in which the needle core for testing telomerase activity was not taken from
the same area of prostate as the needle core specimen for histopathological examination,
resulting in a possible mismatching discrepancy between two specimens. Dye marking in
the prostate was able to decrease the probability of this discrepancy greatly. Another
possibility is that a small number of undetected infiltrating cancerous cells in some needle
biopsy specimens with normal phenotypes may have been responsible for weak positive
telomerase activity in those needle cores, since the TRAP assay is sensitive enough to
detect telomerase activity in as little as 3 cancerous cells. Finally, inhibitors of Taq
polymerase appear to exist in some specimens, causing false-negative results (Figure 3.3).
Such possible inhibitors were further investigated. Since the original needle cores from
the prostate were usually mixed with a little dye, the dyes were tested as suspected
inhibitors of telomerase activity, and were demonstrated to be inhibitors (Figure 3.4).
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Among them, the red and yellow dyes were proven to be stronger inhibitors than the
green dye. Dilution of a high concentration of CHAPS extract from dye-containing
needle cores could alleviate inhibition of the assay (Figure 3.3). It would be prudent to
use dyes shown to be minimally inhibitory toward telomerase when collecting needle
biopsy specimens from patients.
Based on Gleason scores, prostate cancer can be classified into three groups: well
differentiated (score of 2 to 4), moderately differentiated (score of 5 to 7), and poorly
differentiated (score of 8 to 10) (Deshmukh and Foster, 1998). Previous studies revealed
that the Gleason score is tightly correlated with the prognosis of prostate cancer and with
the cancer volume in the patient (McNeal, 1992). In the present study, we first tried to
find a possible relationship between the volume of cancer and relative telomerase
activity. The results suggested that relative telomerase activity is associated with the
volume of histologically-confirmed prostate cancer. Telomerase activity in the needle
cores was further found to be correlated with the Gleason score and pathological
differentiation, in agreement with data previously published (Lin et al., 1998). This
conclusion also suggested that active telomerase may play a role in the carcinogenesis of
prostate carcinoma, and telomerase activity could be considered as a prognostic marker of
prostate cancer. Further analysis of specimens showed that the higher the incidence of
cores with positive telomerase activity, the higher was the Gleason score (Figure 3.5).
These results indirectly confirmed the relationship between the Gleason score and the
volume of cancer.
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Clinically, it is helpful for a pathological diagnosis to collect multiple needle
biopsy specimens, such as sextant needle cores, from the prostate. What we did was to
obtain the needle cores from excised prostates. However, the results above provide a
basis for further clinical use. It can now be concluded that testing telomerase activity in
needle biopsy specimens may not only play an important role in the diagnosis of prostate
cancer but also provide other valuable pathological information for the further therapeutic
evaluations.
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IV. DETECTION OF TELOMERASE ACTIVITY
IN PROSTATIC SECRETION SPECIMENS
A.

RESULTS
In agreement with previously reported data (Sommerfeld et al., 1996), substantial

telomerase activity was observed in lysates from a human prostate cancer cell line, PC-3.
Thus, we used a CHAPS extract of PC-3 cells and CHAPS lysis buffer as positive and
negative controls, respectively. In a serial dilution study of the PC-3 CHAPS lysate,
telomerase activity could be detected in a protein extract corresponding to as little as one
PC-3 cell when using a 34-PCR cycle (Figure 4.1), confirming the high sensitivity of this
assay system to detect telomerase activity in immortal cells.
We initially collected and assayed 15 PFU specimens (Figure 4.2 and Table
4.1 A). Telomerase activity was obviously present in specimens from 2 of 5 prostate
cancer patients (40%), weakly present in specimens from 2 of 5 BPH patients (40%), one
of whom (Figure 4.2, lanes 11-15) had an elevated PSA value (6.0 ng/ml), and
undetectable in 5 specimens from patients free of cancer or BPH. The assay results
showed the typical 6 bp ladder when 1 pi of each specimen was used (Figure 4.2, lanes 4,
5), but when 5 pi of the specimen was used, a negative result was obtained (Figure 4.2,
lanes 2, 3). There appeared to be a high level of inhibitors of telomerase or of Taq
polymerase in the 5 pi aliquots of urine. Dilution decreased the inhibition.
Based on the results obtained from our initial investigation using a relatively
small sample size of 15, we changed the protocol for collecting the clinical specimens,
not only to improve the sensitivity and reliability of the assay, but to determine how
rigorously the specimens needed to be handled in order to consistently detect telomerase
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Figure 4.1. Telomerase activity in PC-3 cells, a human prostate cancer cell line.
Lanes 1-4, telomerase activity in serial dilutions of CHAPS extract, 1000, 100, 10, and 1
cell equivalents, respectively; lane 5, lysis buffer; lane 6, CHAPS extract, 1000 cell
equivalents, pretreated with heat.
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Figure 4.2. Telomerase activity in prostatic fluid-in-urine (PFU) with the addition
of protease inhibitors. Lanes 1-5, from a PCa patient’s PFU; lanes 6-10, from the PFU
of a patient free of cancer with normal serum PSA; lanes 11-15, from a BPH patient’s
PFU; lane 16, lysis buffer; lanes 17, 18, CHAPS extract of PC-3 cells (6 pg protein), with
or without heat pretreatment, respectively. Heat pretreatment, lanes 1, 6, 11; 5 pi PFU
aliquot, lanes 1-3, 6-8, 11-13; 1 pi PFU aliquot, lanes 4, 5, 9, 10, 14, 15.
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Table 4.1. Diagnostic significance of telomerase activity in prostatic fluid specimens
from a hospital-based patient population
Telomerase Activity

A PFU

S. S.

Present

Sup

2

3

5

Absent

Sup

2

8

10

4

11

15

Sup

10

8

18

56%(10/18) ©

E

10

8

18

56% (10/18)©

W

6

12

18

33% (6/18)0

14

4

18

78% (14/18)

Sup

16

14

30

53% (16/30)0

E

24

6

30

Total (n)
B PF1

Present:

Total (n)
C PF2

i

Ca2

Present

Pos2 Neg 2 T (n)2

Sensitivity

Specificity

Positive
Predictive
Value

40% (2/5) ©
80%
(8/10)
50%
(2/4)

80%
(24/30)00

T (n)2

25

5

30

Sup

0

9

9

E

1

8

9

1

8

9

26

13

39

Present

41 ©

12

53

Absent

3©

16

19

44

28

72

Absent

T (n)2
Total (n)
Overall
Results:
D (PFU +
PF1 +
PF2)
Total (n)

i

83% (25/30) ©

89% (8/9)
96%
(25/26)
77% (41/53)
84%
(16/19)
93%
(41/44)

S. S., Sample Source; Sup, supernatant fluids; E, CHAPS extracts from the pellets; W, whole PF;
2 Ca, carcinoma; Pos, positive; Neg, negative; T (n), total (n);
O, ©, ©, O, ©: Significantly different from each other (P <0.05).

100

activity when it was present. We collected two sets of prostatic fluid specimens. In the
first set (PF1), which lacked protease inhibitors, telomerase activity could be detected in
14 of 18 (78%) specimens from PCa patients (Table 4.IB). Positive telomerase
specimens showed only weak signals (Figure 4.3). The sensitivities of the supernatant
fluids (56%) and of the CHAPS protein extracts from the pellets of PF1 specimens (56%)
were the same, indicating that the extracted telomerase was quickly digested without the
protection of protease inhibitors. The sensitivity in whole PF1 specimens (33%) was
significantly lower than that in either the supernatant fluids or the protein extracts of the
pellets.
Protease inhibitors were added to another set of prostatic fluid specimens (PF2,
Table 4.1C). Telomerase activity was detectable in 83% of specimens from PCa patients,
whereas no activity was detectable in 89% of specimens from patients with either a
normal prostate gland or BPH. The signals from the CHAPS extracts of PF2 pellets were
stronger than those from the PF2 supernatants (Figure 4.4). Furthermore, in some
specimens the telomerase activity was increased after heating at 85 °C for 15 min (Figure
4.4, lanes 3, 7), while in other specimens the telomerase activity was diminished but
could not be abolished by such heating (Figure 4.4, lane 1). This is in contrast to the
effect of heating a CHAPS extract of PC-3 cells to 85 °C for 15 min, which essentially
eliminates telomerase activity (Figure 4.4, lane 11). This phenomenon was further
investigated by heating the aliquots of protein extract from a prostate cancer patient
specimen to 85 °C for 60, 15, and 5 min and then determining the amount of telomerase
activity that remained after the heat treatment (Figure 4.5, lanes 2, 3, 4). In addition, a
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Figure 4.3. Telomerase activity in prostatic fluid specimens (PF1) from three PCa
patients (A, B, C) without the addition of protease inhibitors. Lanes 1-3, specimen A;
lanes 4-6, specimen B; lanes 7-9, specimen C; lane 10, lysis buffer; lanes 11, 12, CHAPS
extract of PC-3 cells (6 pg protein), without or with heat pretreatment, respectively.
Whole PF1 (1 pi), lanes 1, 4, 7; PF1 supernatant fluid (1 pi), lanes 2, 5, 8; CHAPS
extract from PF1 pellet (6 pg protein), lanes 3, 6, 9.
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3 4 5 6 7 8 9 10 11 12

Figure 4.4. Telomerase activity in prostatic fluid specimens (PF2) from two PCa
patients (D, E) with the addition of protease inhibitors. Lanes 1-4, specimen D; lanes
5-8, specimen E; lane 9, lysis buffer; lanes 10, 11, CHAPS extract of PC-3 cells (6 pg
protein), without or with heat pretreatment, respectively. PF2 supernatant fluid (1 pi),
lanes 1, 2, 5, 6; CHAPS extract of PF2 pellet (6 pg protein), lanes 3, 4, 7, 8. Heat
pretreatment, lanes 1, 3, 5, 7; no heat pretreatment, lanes 2, 4, 6, 8.
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Figure 4.5. Effect of varying durations of heat pretreatment on telomerase activity
in the CHAPS extract of a PF2 specimen pellet. Lane 1, an aliquot (6 pg protein)
preheated at 85 °C for 15 min followed by RNase A pretreatment at 37 °C for 30 min;
lanes 2, 3, 4, aliquots (6 pg protein each) preheated at 85 °C for 60 min, 15 min, and 5
min, respectively; lane 5, an aliquot (6 pg protein) without heat pretreatment; lane 6, lysis
buffer; lanes 7, 8, CHAPS extract of PC-3 cells (6 pg protein), without or with heat
pretreatment, respectively.
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double pretreatment was performed which involved heating at 85 °C for 15 min followed
by exposure to RNase A (0.2 pg/pl) for 30 min at 37 °C (Figure 4.5, lane 1). Telomerase
activity was still detectable after an hour at 85 °C. No telomerase activity was detectable
in the specimens pretreated with both heat and RNase A. Our results suggest that a heatpretreatment is not always an appropriate negative control for telomerase activity in
prostatic fluid specimens. On the contrary, heat-pretreatment of some of the specimens
improves the ability to detect telomerase activity.
To search for possible factors which influence telomerase activity in prostatic
fluid specimens, we mixed the CHAPS extract of the pellet from a PCa patient with an
aliquot of PC-3 cell extract (Figure 4.6). The telomerase activity in the mixture (lane 6)
was significantly decreased compared with that in the original PC-3 cell extract (lane 9).
A heat-pretreatment did not eliminate the telomerase activity present in the mixture (lane
5). The effects of the protease inhibitors on telomerase activity were also tested (Figure
4.7). Telomerase activity in PC-3 CHAPS extracts was lower when the protease
inhibitors were included in the reaction than when they were not.
Overall, 77% of specimens from confirmed-PCa patients were positive for
telomerase activity. Only 16% of the specimens from BPH or normal patients tested
positive. The overall positive predictive value (PPV) was 93% (Table 4.ID).
We also analyzed the relationship between telomerase activity in the prostatic
fluid specimens and the PSA values of patients, and found that telomerase activity had a
strong correlation with the PSA levels (Table 4.2A). Patients with PSA values >4 ng/ml
had telomerase activity in their prostatic secretion specimens 79% of the time, while only

108

Figure 4.6. Inhibition of telomerase activity in a CHAPS extract of PC-3 cells (0.3
Hg protein) by the addition of CHAPS extract of the pellet from a PF2 specimen (0.3
pg protein). Lanes 1-3, CHAPS extract of the pellet of the specimen (0.3 pg protein
each); lanes 4-6, CHAPS extract of the specimen mixed with CHAPS extract of PC-3
cells; lanes 7-9, CHAPS extract of PC-3 cells (0.3 pg protein each); lane 10, lysis buffer.
RNase pretreatment, lanes 1, 4, 7; heat pretreatment, lanes 2, 5, 8; no pretreatment, lanes
3,6, 9.
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Figure 4.7. Inhibition of telomerase activity in a CHAPS extract of PC-3 cells (6 ng
protein) by the addition of protease inhibitors. Lanes 1-3, no protease inhibitors
added; lanes 4-6, protease inhibitors added; lane 7, lysis buffer. RNase pretreatment,
lanes 1, 4; heat pretreatment, lanes 2, 5; no pretreatment, lanes 3, 6.
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Table 4.2. The correlation of either PSA value (A) or Gleason score (B) with
telomerase activity in prostatic fluid specimens from a hospital-based patient
population
Telomerase Activity

A

B

Overall
results:
(PFU +
PF1 +
PF2)
Overall
Results:
(PFU +
PF1 +
PF2)

PSA
Value

Pos 2 Neg 2 Total (n)

Sensitivity

>4

37 0

10

47

79% (37/47)

^4

70

18

25

Total (n)

44

28

72

>4

31 ©

5

36

<4

5 ©

4

9

Total (n)

36

9

45

72%

i

Gleason
Score

Specificity

Positive
Predictive
Value

(18/25)

i

the normal range of the PSA value is <4 ng/ml;
2 Pos, positive; Neg, negative;
O, ©: Significantly different from each other (P <0.05).
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84%
(37/44)

86% (31/36)
44% (4/9)

86%
(31/36)

28% of the patients with PSA values <4 ng/ml had telomerase activity in their prostatic
secretions. Using this comparison, the PPV of the TRAP assay for an elevated PSA was
84%.

Telomerase activity was also correlated with the Gleason scores of the patients
(Table 4.2B). Telomerase activity could be detected in 86% of prostatic fluid specimens
from PCa patients with Gleason scores >4, and 56% of PCa patients with Gleason scores
<4 also had telomerase activity in their prostatic fluid specimens. Using the Gleason
score of 4 as the dividing point for these two groups produced a PPV of 86%.

B.

DISCUSSION
Since the development of the TRAP assay (Kim et al., 1994), telomerase activity

has been detected in a wide variety of malignant tumors, including prostate cancer (Kim
et al., 1994; Shay and Wright, 1996). On this basis, telomerase appears to have promise
as a tumor marker. Telomerase activity is detectable in invasively collected tissue
specimens from PCa patients indicating that the TRAP assay could be useful as a
diagnostic tool for PCa (Sommerfeld et al., 1996; Lin et al., 1997 & 1998; Takahashi et
al., 1997). However, telomerase detection in noninvasively obtained body fluids, such as
prostatic secretions, is likely to be more practical in the diagnosis of prostate cancer
because noninvasive diagnostic procedures achieve more patient compliance and are less
expensive.
Clinically, prostatic adenocarcinoma arises in the acinar and proximal ductal
epithelium of the prostate gland and accounts for over 95% of prostatic cancers (Trump et
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al., 1997). Prostatic fluids contain proteases, lipids, metal ions and amines secreted
continuously from acinar cells of the prostate gland (Grover and Resnick, 1995).
Furthermore, a few exfoliated cells from the prostate and telomerase from those cancer
cells might be in prostatic secretions. Telomerase activity has been detected in exfoliated
cells present in urine from bladder carcinoma patients (Yoshida et al., 1997b; Kinoshita et
al., 1997) as well as in colonic luminal washings from colon carcinoma patients (Yoshida
et al., 1997a).
The present study focuses on determining the diagnostic value of the TRAP assay
applied to prostatic secretion specimens. More than 70% of 53 PCa patients showed
positive telomerase activity in their specimens; the PPV was 93% (Table 4.1). More than
80% of 19 normal or BPH patients were negative for telomerase activity.
In our initial study with PFU specimens (Figure 4.1 and Table 4.1 A), only 2 of 5
PCa patients had positive telomerase activity. Although PFU specimens were easier to
collect than pure prostatic fluid specimens, it was suspected that low concentrations of
telomerase in the voided urine specimens might cause false negative results and a low
sensitivity. Two specimens from BPH patients had weakly positive telomerase activity,
which implied the possibility of undetected prostate cancers in these patients (Stamey and
Kabalin, 1989). All specimens from normal patients showed negative telomerase
activity, consistent with previous reports (Kim et al., 1994; Shay and Wright, 1996).
Nevertheless, telomerase activity could be detected in some of the PFU specimens. The
problems associated with the analysis of PFU specimens prodded us to develop a
different method of collecting prostatic secretion specimens.
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Consequently, we began collecting pure prostatic fluid from individuals.
Collecting prostatic fluid without urine decreases the possibility of false positive or
negative results in the TRAP assay resulting from factors in urine which could affect the
assay. Since a prostatic fluid specimen may contain exfoliated cancer cells, we also
looked at the telomerase activity present in the CHAPS protein extract of the pellet from
each prostatic specimen. Fourteen of 18 prostatic fluid specimens from PCa patients in
the PF1 group showed positive telomerase activity (supernatant fluids and/or CHAPS
extracts). Moreover, positive telomerase activity could be found in 25 of 30 specimens
from PCa patients in the PF2 group. The overall sensitivities of detection of telomerase
activity between PF1 (78%) and PF2 (83%) had no statistically significant difference.
However, the intensities of positive telomerase signals in PF1 were all weak, and the
sensitivity (80%) from the protein extracts in PF2 was significantly higher than that from
either the protein extracts (56%) or the supernatant fluids (56%) in PF1, suggesting that
protease inhibitors may be the cause for the increase in sensitivity. Negative telomerase
activity from PCa patients could be attributed to the degradation of telomerase resulting
from the absence of protease inhibitors in PF1, which may have caused the amount of
telomerase to fall below a measurable limit. The pellets, obtained by centrifugation, of
fresh prostatic fluid specimens with protease inhibitors added appear to be the better
specimen source for detecting telomerase activity.
Telomerase is a ribonucleoprotein enzyme whose activity depends on both its
RNA and protein components. Numerous data have shown that its activity can be
eliminated by a pretreatment with either RNase A or heat (Greider and Blackburn, 1987;
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Morin, 1989). However, the results from some PF2 specimens showed that the
telomerase activity could be increased after heat-pretreatment. In other PF2 specimens,
the telomerase signals became weakened, but could not be totally abolished by pre
heating. This suggested that inhibitors of telomerase are present in pure prostatic fluid
specimens which bind tightly to the telomerase enzyme. Heat pretreatment appears to be
inactivating the inhibitor rather than inactivating the telomerase.
Serum PSA is commonly used as a marker for prostate cancer. In general, the
higher the PSA level, the greater is the likelihood of an advanced pathologic stage
(Stamey and Kabalin, 1989). Serum PSA level has been found to correlate with tumor
volume and is an important predictor of tumor progression and prognosis (Ohori et al.,
1994a). In this study, we demonstrated that telomerase activity is highly correlated with
PSA levels. In addition, we showed that a strong correlation exists between the presence
of telomerase and a Gleason score >4. Therefore, the detection of telomerase in prostatic
fluid appears to serve effectively as both a diagnostic and a prognostic marker for prostate
cancer. In our study, 93% of patients who showed positive telomerase activity in their
prostatic secretion specimens also had prostate cancer. In contrast, only about 35% of
males with serum PSA levels >4 ng/ml are found to have prostate cancer (Catalona and
Smith, 1994). Therefore, the presence of telomerase in prostatic fluid may be a more
specific cancer marker than PSA for diagnosing prostate cancer.
In conclusion, the PCR-based TRAP assay is sensitive enough to detect
telomerase activity in noninvasively obtained prostatic fluid. Telomerase activity is
detectable in a high percentage of prostatic fluid specimens from prostate cancer patients,
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but not in the specimens from normal patients. The prostatic fluid specimens can be
collected easily and with minimal discomfort or risk to patients. The ability to detect
telomerase activity in those specimens suggests that the TRAP assay has the potential of
playing a role in the diagnosis of prostate cancer.
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V. EVALUATION OF THE TELOMERASE PCR ELISA
FOR DETECTION OF CANCER IN PROSTATE NEEDLE
BIOPSY AND PROSTATIC FLUID SPECIMENS
A.

RESULTS

1.

Telomerase Activity in Prostate Needle Biopsy Specimens Determined by the
PCR-ELISA Method
Using telomerase PCR ELISA kits, we examined telomerase activity in 48 sextant

needle biopsy specimens from 7 PCa patients. Based on a suggestion from the kit, the
sample could be considered positive if AA is >0.2, but the relative activity in units
corresponding to 0.2 AA in each experiment varied a little from 5.8 to 7.5 units because
of a deviation of the slopes of the standard curves. The mean activity for the positive
cutoff point was 6.9 ± 0.7 units (mean ± SD). At the same time, we also confirmed the
activity in these specimens using the radioisotope-requiring TRAP assay. The activity in
units for the positive cutoff point could be determined when the mean density was equal
to zero, which was also varied because of a deviation of the slopes of the standard curves,
and the mean activity at this point was 7.6 ±3.2 units.
For the PCR ELISA, among 32 prostate needle cores with histopathologically
confirmed cancer, 29 (91%) showed positive telomerase activity. On the other hand, 11
of 16 (69%) needle cores without histologically-confirmed cancer had no activity, while
the remaining five specimens showed weak activity. The positive predictive value (PPV)
and negative predictive value (NPV) were 85% and 79%, respectively. The mean activity
per needle core containing cancer cells was 24.5 ± 28.4 units, which is significantly
higher than that without cancer cells (7.2 ± 2.2 units) (Table 5.1). Similar results were
obtained when the radioisotope-requiring TRAP assay was used to test telomerase
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Table 5.1. Telomerase activity tested by two methods in needle biopsy specimens

Method
Telomerase Activity

PCa

i

the Radioisotope-requiring
TRAP Assay

the PCR ELISA
Pos2

Neg2

Present

29 0

3©

32

Absent

50

11©

16

Total (n)

34

14

48

Sensitivity

Negative Predictive
Value (NPV)

Pos3

Neg3

24.5 ±28.4©

28 0

4©

32

25.6 ±27.8©

7.2 ±2.2©

30

13©

16

7.3 ±1.8©

31

17

48

91%
(29/32)

Specificity
Positive Predictive
Value (PPV)

Total (n) Unit/Speci.4

Total (n)

88%
(28/32)

69%
(11/16)

81%
(13/16)

85%
(29/34)

90%
(28/31)
79%
(11/14)

76%
(13/17)

1 needle core specimens were further confirmed by the pathohistological examination.
2 Pos (positive): AA: ^0.2 or the mean activity: 6.9 ± 0.7 units; Neg, negative;
3 Pos (positive): the activity: 7.6 ±3.2 units; Neg, negative;
4 the mean activity per specimen (Unit/Specimen)
O, ©, ©, O, ©, ©: significantly different from each other {P <0.001).
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Unit/Speci.4

activity in these specimens, telomerase activity was positive in 28 of 32 specimens
containing pathohistologically confirmed cancer cells (88%), while only 3 of 16 needle
cores without histologically confirmed cancer cells had weak telomerase activity (19%).
Compared with the data from the PCR ELISA group, the TRAP assay consistently
yielded higher PPV and NPV values, namely, 90% and 76%, respectively. Also, in
contrast to the relatively lower average activity (7.3 ±1.8 units) in the specimens without
cancer cells, the average activity per specimen containing cancer cells (25.6 ± 27.8 units)
was significantly higher and close to that (24.5 ± 28.4 units) found in the PCR ELISA
group (Table 5.1). For each specimen, relative telomerase activities from two methods
could also be compared with each other. As hoped for, telomerase activity in the cores
tested by one method usually closely matched with the activity tested by the other (Figure
5.1). The data above suggested that the telomerase PCR ELISA was methodologically
sensitive enough to detect telomerase activity in a small quantity of needle biopsy tissue
by showing a close parallel to the activity confirmed by the radioisotope-requiring TRAP
assay.
2.

Telomerase Activity in Prostatic Fluid Specimens Determined by the PCRELISA Method
To evaluate the possible application of the PCR ELISA in detecting telomerase

activity in prostatic fluid specimens, we examined 18 specimens with protease inhibitors
added, half of them being from PCa patients and the other half from patients clinically
confirmed as cancer-free. The data showed that the signals from the CHAPS extracts of
the pellets of prostatic fluid with protease inhibitors added were stronger than those from
the supernatants. Moreover in some specimens the telomerase activity was increased
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after a pre-heating at 85 °C for 15 min. Therefore, we designed experiments in which
telomerase activity was determined in both original and preheated samples of CHAPS
extract of the pellet and of the supernatant fluid from each specimen. The specimen from
a patient was considered to have positive telomerase activity if at least one sample from
the specimen showed positive activity. The PCR-ELISA and the radioisotope-requiring
TRAP assay were performed in parallel to determine the activity in the specimens.
Because of the relatively lower activity present in these specimens compared with the
activity found in tissue specimens, we changed the positive cutoff point from 0.2 AA to
0.1 AA. This caused an increase in the sensitivity from 44% (data not shown) to 78%
without affecting the specificity. For further semi-quantitative analysis, a semi-log
standard curve from serial dilution measurements of a PC-3 cell extract was set up for
each experiment. The mean activity at the positive cutoff point from several standard
curves was 7.6 ± 0.5 units. The positive cutoff point for the radioisotope-requiring TRAP
assay was 7.0 ± 0.2 units on the average.
Using both the PCR-ELISA and the radioisotope-requiring TRAP assay,
telomerase activity was detected in 7 of 9 specimens (78%) from PCa patients, whereas
only 1 of 9 specimens (11%) from the cancer-free patients showed weak activity. The
PPV and NPV were 88% and 80%, respectively. Interestingly, the mean activity for the
specimens from cancer patients was only 7.1 ± 1.5 units for the PCR-ELISA and 7.2 ±
1.8 units for the radioisotope-requiring TRAP assay. Both of those values of telomerase
activity were just slightly higher than the values of 6.2 ± 0.4 and 5.7 ± 0.9 units,
respectively, obtained from the cancer-free patients (Table 5.2). Thus, weak telomerase
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Table 5.2. Telomerase activity tested by two methods in prostatic secretion
specimens

Method
Telomerase Activity

PCa

i

the Radioisotope-requiring
TRAP Assay

the PCR ELISA
Pos 2 Neg 2 Total (n) Unit/patient4

Pos 3

Present

70

2©

9

7.1 ±1.5©

7©

20

9

7.2 ± 1.8©

Absent

1 O

8©

9

6.2 ±0.4©

1©
8

80
10

9
18

5.7 ±0.9©

Total (n)

8

10

18

Sensitivity

78%
(7/9)

Specificity
Positive Predictive
Value (PPV)
Negative Predictive
Value (NPV)

Neg 3

78%
(7/9)
89%
(8/9)

89%
(8/9)

88%
(7/8)

88%
(7/8)
80%
(8/10)

80%
(8/10)

i

patients were clinically and pathologically diagnosed;
2 Pos (positive): AA: ^0.1 or the mean activity: 7.6 ± 0.5 units; Neg, negative;
3 Pos (positive): the mean activity: 7.0 ± 0.2 units; Neg, negative;
4 the mean activity per patient (Unit/patient);
O, ©, ©, O: significantly different from each other (P <0.001);
©, ©: not significantly different from each other {P >0.05).
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Total (n) Unit/patient4

activity was usually detected in all of these prostatic fluid specimens. Nevertheless, the
data above indicate that the PCR ELISA kit could be used to detect telomerase activity in
prostatic fluid specimens by showing results comparable to the radioisotope-requiring
TRAP assay.

B.

DISCUSSION
Since the highly sensitive PCR-based TRAP assay was created in 1994 (Kim et

ah, 1994), numerous published data have shown that telomerase is active in about 85% of
human cancers tested, but the activity is absent in most human somatic cells and tissues
(Kim et ah, 1994; Shay and Wright, 1996; Shay and Bacchetti, 1997). This suggests that
telomerase activity may be a promising molecular marker for the diagnosis of human
cancer and that the TRAP assay for the detection of telomerase activity is sensitive and
specific enough to be employed for this process. However, the conventional TRAP assay
is methodologically radioisotope-involved, which is somewhat hazardous. The result is
visualized by autoradiography after gel electrophoresis, which is time consuming and
inconvenient. Finally, limited linearity of the results affects the accurate evaluation of
telomerase activity in different cancers. These disadvantages may limit clinical
application. In recent years, several modifications of the conventional TRAP assay have
been made to overcome these disadvantages. The changes include the use of modified
primers to improve the specificity of PCR amplification (Tatematsu et al., 1996; Kim and
Wu, 1997), the introduction of an internal standard in the assay to increase the reliability
and linearity (Wright et al., 1995; Kim and Wu, 1997), the use of fluorescent or
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biotinylated primers or probes in the assay instead of the use of 32P radioisotope
(Ohyashiki et ah, 1996; Savoisky et ah, 1996; Aldous and Grabil, 1997; Gelmini et ah,
1998; Uehara et ah, 1999), and the application of other biotechniques to reduce testing
time and to simplify the procedures (Fujita et ah, 1998; Hirose et ah, 1998; Sun et al.,
1998; Cheng et ah, 1999). All of these trials have promoted an interesting evolution of
the assay, although some disadvantages still exist in each modified assay.
Here we selected the telomerase PCR-ELISA, a modified TRAP assay developed
by Boehringer Mannheim, to evaluate its possible clinical use in the diagnosis of prostate
cancer. In the process, the radioisotope-requiring TRAP assay was necessarily performed
along with this new PCR-ELISA. Testing different protein amounts of PC-3 cell extract
as positive controls in both assays allowed semi-quantitative analysis, by means of
standard curves, and also paired results from a given specimen. From several standard
curves in the experiments it was seen that all exhibited good linearity from 10 units (0.06
pg PC-3 cell extract) to 1000 units (6 pg PC-3 cell extract), indicating a good relationship
to the quantities of DNA synthesized after PCR amplification. Significant deviations
appeared on the spots outside this range (Figure 2.5). Similar results could be seen in the
standard curves from the radioisotope-requiring TRAP assay.
For prostate needle biopsy specimens, telomerase activity detected in the PCRELISA matched well with the activity determined in the conventional TRAP assay
generally. However, the results showing lower or weak telomerase activity from both
assays occasionally did not parallel each other very well, resulting in a relatively lower
specificity (69%) in the PCR-ELISA group. Statistical analysis suggested that the PCR-
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ELISA kits could be clinically used to detect telomerase activity in prostate needle cores,
which usually contain a very small amount of prostate tissue, instead of the conventional
TRAP assay. In other words, the PCR-ELISA could be applied practically, not only for
the detection of telomerase activity in sextant needle biopsy specimens but also for a
further indication of the possible cancer regions in the prostate based on the results.
Comparing specimens obtained from PCa patients for telomerase activity testing,
most of the prostatic fluid specimens, even with added protease inhibitors, would be
expected to exhibit the weaker activity. Such specimens usually contain very few cancer
cells and also appear to have in them a heat-labile inhibitor of telomerase. Because the
telomerase PCR-ELISA seemed less reliable than the radioisotope-requiring TRAP assay
for detecting low levels of telomerase activity, we attempted to bolster the reliability of
the former method by testing multiple samples of a single specimen. These samples
included original and preheated samples of the supernatant from a specimen and of the
CHAPS extract of the specimen’s pellet. By this multiple sample testing, we sought to
provide more chances for the manifestation of positive telomerase activity and to
decrease concomitantly the probability of obtaining a false-negative result. When
prostatic fluid specimens from 9 prostate cancer patients were subjected to multiple
telomerase PCR-ELISA testing (total of 36 tests), only 9 were positive. However, these
were distributed among 7 out of the 9 patients. Assuming the correctness of any positive
result, the sensitivity by this mode of testing was 78% (Table 5.2). In contrast, when
prostatic fluid specimens from 9 cancer-free patients were subjected to multiple
telomerase PCR-ELISA testing (total of 36 tests), only 1 was weakly positive.
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Interpreted as before, 8 out of 9 cancer-free patients were thereby shown to be free of
cancer (specificity 89%). On the other hand, when multiple sample testing was also
applied for determining telomerase activity by the conventional TRAP assay, similar data
were obtained (Table 5.2). Overall, the activity and statistical results of the conventional
TRAP assay matched well those of the PCR-ELISA, even though lower activities in a
few samples from both assays were not quite parallel, due to possible methodological
reasons.
We also tried to analyze the data to look for a better sample source for testing in
the PCR-ELISA. Interestingly, 8 of the 10 samples showing positive activity were heatpretreated aliquots of the CHAPS extracts of specimen pellets, suggesting that the pellet
from pure prostatic fluid contains more telomerase molecules than the supernatant fluid,
and that heat pretreatment inactivates some inhibitor of telomerase rather than
inactivating the telomerase.
In summary, the PCR-ELISA is methodologically capable of determining
telomerase activity in prostate needle cores and in prostatic fluid specimens. It could
therefore be used for the diagnosis of prostate cancer if multi-sample testing and a proper
adjustment of the kit-suggested positive cutoff point in testing prostatic fluid specimens
are introduced into the procedure.
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VI. CONCLUSIONS AND FUTURE STUDIES

A.

CONCLUSIONS
Our initial study of telomerase activity in the PC-3 human prostate cancer cell line

demonstrated that the PCR-based TRAP assay we set up was sensitive enough to detect
telomerase activity from a single PC-3 cell. The known linkage between telomerase
activity and cancer cells was thus confirmed and the assay was shown to be sufficiently
sensitive for possible clinical use.
Further studies indicated that this highly sensitive TRAP assay was capable of
detecting telomerase activity in the small amount of prostatic tissue obtained in sextant
needle cores. This positive activity was usually detected in the needle cores from
cancerous regions of the prostate, whereas activity was usually not demonstrable in the
needle cores from cancer-free regions. Therefore, telomerase activity now appears to be a
promising diagnostic marker for prostate cancer. Telomerase activity in sextant needle
cores was also proven to be related to the Gleason score, to differentiation of the tumor,
and to the cancer volume, suggesting that telomerase activity may be involved in the
process of development of prostate cancer and that the activity can serve as a prognostic
marker for prostate cancer. Finally, green, red, and yellow dyes are all able to inhibit the
telomerase assay methodologically.
It is essentially important that telomerase activity was detectable in a high
percentage (77%) of noninvasively obtained prostatic fluid specimens from prostate
cancer patients, but not in the specimens from normal patients. Prostatic fluid specimens
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usually contain a small number of cancerous cells, but can be collected easily and with
minimal discomfort or risk to patients. The ability to detect telomerase activity in those
specimens suggested that the highly sensitive TRAP assay has the potential of being
employable in screening for the presence of early prostate cancer. We also determined
that the pellets of fresh prostatic fluid specimens with protease inhibitors added appear to
be the better specimen source for detecting telomerase activity methodologically.
Statistical analysis further revealed that telomerase activity correlated well with the serum
PSA level and the Gleason score of prostate cancer patients and that the TRAP assay had
a higher specificity than PSA testing in the detection of prostate cancer. This suggested
that the presence of telomerase in prostatic fluid may be a more specific diagnostic
marker than PSA for prostate cancer.
A comparison study demonstrated that telomerase activity determined by the
PCR-ELISA method usually matched well with the activity determined by the
radioisotope-requiring TRAP assay in both prostate needle cores and prostatic fluid
specimens. This suggested that the PCR-ELISA was methodologically adaptable and
appropriate for clinical use in the diagnosis of prostate cancer, although multi-sample
testing and a proper adjustment of the kit-suggested positive cutoff point in testing
prostatic fluid specimens were recommended.

B.

FUTURE STUDIES
In the process of detecting telomerase activity in PF specimens with protease

inhibitors added, we found that protease inhibitors appeared to bind to telomerase,
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inhibiting its activity. This inhibition interfered with obtaining a reliable assay. Heat
pretreatment was able to release the inhibition. Since there are four kinds of protease
inhibitors in the solution, it is necessary to determine which of these is causing the
telomerase inhibition. Thus, the effect of each protease inhibitor alone on telomerase
activity should be determined. Alternatively, a group of protease inhibitors that have no
effect on telomerase activity could be sought.
Future studies may also include an evaluation of telomerase activity in the
ejaculate. A logical and easy way to get prostatic fluid would be to collect fresh
ejaculates from patients because the ejaculates contain a large volume of prostatic fluid
and numbers of mature sperm which have been proven to have a negative telomerase
activity (Wright et al., 1996). Testing telomerase activity in the ejaculate may provide
another convenient way for the detection of prostate cancer.
Additional future studies may determine whether the catalytic subunit of human
telomerase, which contains reverse transcriptase from hTERT gene expression, could be
targeted as a potential marker of prostate cancer. It has been demonstrated that the
expression of hTERT seems to be a rate-limiting determinant of human telomerase
activity. Up-regulation of hTERT is always associated with an increase in telomerase
activty, and may play a critical role in the development of some kinds of cancer (Bodnar
et al., 1998; Hisatomi et al., 1999; Kyo et al., 1999; Liu et al., 1999; Xu et al., 1999).
Therefore, the role of hTERT in the development of prostate cancer needs to be further
evaluated. In the process, hTERT mRNA expression in a few prostate cancer cell lines
and in fresh prostatic tissue with or without cancerous cells could be analyzed by RT-
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PCR, Northern blotting, and even by in situ hybridization. The protein level from
hTERT expression could be further evaluated by Western blotting if antibody against the
hTERT protein becomes available.
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